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ABSTRACT

THE DEVELOPMENT OF NOVEL PLATFORMS FOR THE IMAGING OF CANCER BY
POSITRON EMISSION TOMOGRAPHY
by
Brendon E. Cook

Advisors: Brian M. Zeglis and Jason S. Lewis

The role of antibody-based imaging of cancer by positron emission tomography (PET)
has expanded significantly in recent years and is poised to radically alter the way that cancer is
diagnosed and treated. However, one hurdle that remains is the potentially harmful radiation
dose that comes from these imaging agents, as the long circulation time of antibodies (days to
weeks) necessitates the use of radionuclides with comparable physical half-lives (i.e.

89

Zr,

124

I,

etc.). One particularly promising solution is the use of the inverse electron demand Diels-Alder
(IEDDA) reaction between a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene (TCO) for
pretargeting. By separately injecting antibody and radioligand and allowing the two to “click” in
vivo, overall dose to the patient can be reduced nearly 45-fold. The first half of the dissertation
to follow seeks to optimize both antibody and radioligand, while setting the stage for eventual
clinical translation.

The second half explores the emergence of enzyme-responsive

nanomaterials in an attempt to develop a PET imaging agent for MMP-9 activity.
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Chapter 1: An Introduction to Pretargeting
Nuclear imaging plays a crucial role in the diagnosis of cancer and subsequent
monitoring of treatment. It can be divided into two primary categories: positron emission
tomography (PET) and single-photon emission computed tomography (SPECT).

SPECT

imaging involves the detection of gamma rays originating primarily from metastable, excitedstate nuclei. These gamma rays are registered on special detectors that allow for the origin of the
decay event to be determined computationally.

Alternatively, PET imaging relies on the

emission of positrons from the nucleus of certain unstable isotopes when a proton is converted
into a neutron. The energy of this positron (i.e. the energy with which it is ejected from the
nucleus) will influence the distance it travels before slowing enough to encounter an electron.
The resulting matter/antimatter annihilation event produces two antiparallel gamma ray photons
that can be detected simultaneously to determine their point of origin. While both PET and
SPECT see widespread clinical use, this work will focus exclusively on PET radiotracer
development.
PET imaging facilitates the in vivo detection of radioactivity, typically administered
intravenously, that has been bound to some vector.

This vector will often localize the

radionuclide to areas of diseased tissue with the exclusion of healthy areas, allowing a clinician
to derive information about the disease.

The most widely used imaging agents today are

radiotracers derived from small molecules. These tracers capitalize on certain hallmarks of
cancer such as increased glucose metabolism (18F-FDG), cell division (18F-FLT), or hypoxia
(18F-FMISO) to identify likely regions of disease.1, 2 While these tracers typically have broad
applicability, their results can be misinterpreted and are not always accurate. For example, the
most commonly used PET tracer,

18

F-FDG, is taken up via the glucose metabolic pathway and

1

can localize in tissue that has a larger appetite, such as a tumor. While it has proven highly
effective at detecting a wide range of cancers, it becomes difficult or impossible to distinguish
cancer from other diseases that present increases in metabolism, such as tissue inflammation.3 In
addition, some organs, such as the brain, exhibit high levels of glucose metabolism when
healthy, precluding the use of 18F-FDG.4
The lack of specificity found in metabolic imaging agents warrants the need for a second
approach to molecular imaging. To this end, it has been found that cancerous cells express
molecular characteristics that are either not present on healthy cells or present only at very low
levels. Additionally, many of these markers can give information useful to clinicians, such as
how likely a tumor is to metastasize or how well a patient would respond to a given treatment.
Such biomarkers are then desirable targets as they both differentiate cancerous tissue and provide
histological information as well.
Targeting extracellular biomarkers typically capitalizes on naturally-occurring receptorsubstrate interactions best illustrated by the use of antibodies. Antibodies are proteins produced
by an immune cell to target a single epitope, typically present on the surface of foreign cells, and
serves as a beacon of sorts to alert macrophages that the target in question needs to be destroyed.
Through the manipulation of antibody-secreting B-cells, genetic engineering, and chemical
modification, antibodies can be modified to target an exceptionally wide range of epitopes, both
natural and synthetic. As such, antibodies will bind their antigen with almost unparalleled
specificity and affinity, making them nearly ideal as targeting vectors.5 It follows then that
conjugation of radioisotopes to the antibody structure allows for the directed localization of
radiation to sites of antigen expression. Selecting antibodies that target cancer-specific antigens

2

can therefore provide meaningful data, both on the location and morphology of the tumor and,
perhaps more importantly, on its histological characteristics as well.
Gathering these data through an imaging modality can spare patients from having to
undergo more invasive diagnostic procedures, such as a surgical biopsy. Such biopsies are rarely
able to evaluate the whole tumor, and in cases where the malignancy is not homogeneous
throughout the growth, important information can be easily missed simply by sampling the
wrong location.6 Histological information obtained by PET on the other hand provides a holistic
view of the disease and can better inform treatment as a result. Antibody-based PET imaging,
“immunoPET”, has emerged as part of the paradigm-shift towards personalized medicine and
there have been numerous clinical trials demonstrating its efficacy in many diseased states.7-9
Despite these successes, one important concern centers on the increased radiation burden
for patients who are subjected to repeated PET scans.
radiological imaging, small molecule tracers such as

While certainly a concern in all
18

F-FDG use short-lived isotopes,

physically limiting the amount of time that patients remain radioactive, while also clearing
quickly due to their fast pharmacokinetics. In contrast, antibodies clear from circulation much
more slowly due to their size (~150,000 Da in contrast to the 180 Da of FDG) resulting in longer
delay times between radiopharmaceutical injections and imaging time. This delay is often
several days for immunoPET, while small molecules are typically same-day injection and PET
scan. As such antibodies labeled with radioactive isotopes, or radioimmunoconjugates, must be
labeled with longer-lived radioisotopes than small molecule tracers.
Small molecule radiotracers are most typically labeled with positron-emitting
radioisotopes whose half-lives are on the order of minutes to hours. Most commonly used are
11

C,

13

N,

18

F,

68

Ga, and

64

Cu with half-lives of 20.3 min, 9.97 min, 109.77 min, 67.7 min, and
3

12.7 hours respectively. In contrast, antibodies are most often labeled with

89

Zr and

131

I with

half-lives of 78.4 hrs and 8.02 days respectively. Longer isotopic half-lives paired with longer
physiological half-lives can lead to a significant radiation dose to the patient. Additionally,
patients often require repeated scans over the course of their treatment, necessitating efforts into
minimizing this dose while maintaining the antibody’s targeting efficacy.
While there have been a number of proposed solutions, such as the use of antibody
fragments, the most promising is, perhaps, the use of pretargeting. Pretargeting is an imaging
method by which administration of the radioligand is separate from administration of the
antibody, allowing the two to combine in vivo.

This serves to substantially reduce the

radioactive dose to the patient, as well as reduce the amount of time between administration of
the radioactivity and imaging. Pretargeting typically occurs in four steps (Figure 1.1): first,
antibody is injected that is modified to bind both antigen and radioligand; second it is allowed to
accumulate at the site of antigen expression and clear from any non-target tissues; third,
radioligand is injected; fourth, this radioligand circulates throughout the body and binds to the
modified antibody. The small size of the radioligand allows it to clear rapidly over a matter of
hours, leaving activity only at the tumor site for imaging.

4

Figure 1.1: Schematic of cancer pretargeting.

There are primarily four methods to facilitate this in vivo ligation (Figure 1.2).10 The
first capitalizes on the extraordinary affinity between biotin, a 244-Da small molecule, and
streptavidin (SA), a bacterially-derived tetrameric protein. This strategy was one of the first
pretargeted approaches to emerge and found success in the attachment of SA to the antibody and
biotinylation of a radiolabeled small molecule. After promising preclinical data, a number of
clinical trials emerged to evaluate SA-biotin pretargeting for both imaging and therapy.11,

12

While results were promising, it was found that the bacterially-derived SA resulted in elevated
levels of human antistreptavidin antibody suggesting that repeated administrations could result in
a severe allergic reaction. This has proven to be a near-fatal flaw, and little work has been done
with this system in the last decade.
Second is the use of bispecific antibodies; IgGs that have been modified to bind multiple
haptens simultaneously. This allows the antibody to bind both the tumor associated antigen as

5

well as a radiolabeled hapten. While bispecific antibodies have demonstrated their merits in a
wide range of effective applications, concerns remain with respect to their lack of modularity and
the extensive re-engineering needed for each new antibody.13 The third example has been
developed to exploit the base-pairing selectivity of nucleic acids through the use of
oligonucleotides. Oligonucleotides are DNA bases that have been modified with unnatural
backbones to avoid detection by digestion enzymes. Despite some enticing preclinical data,
intrinsic hydrophobicity of the molecules and binding affinity are still of concern.10

Figure 1.2: Four principal mechanisms of in vivo pretargeting. This diagram was originally
published in JNM. Mohamed Altai et al. J Nucl Med 2017; 58:1553-1559.10

The fourth and final pretargeting conjugation method to be discussed here is the inverse
electron demand Diels-Alder (IEDDA) reaction that occurs between a 1,2,4,5-tetrazine (Tz) and
a trans-cyclooctene (TCO) (Figure 1.3), and shall be the focus for the remainder of this work.
This reaction was first considered for use in bioconjugation in 2008 by Blackman, Royzen, and
Fox, where they describe a water-stable 3,6-diaryl-s-tetrazine reacting with trans-cyclooctene
under biologically relevant conditions.14 The exceptionally fast kinetics allow the coupling to

6

occur irreversibly even under the extremely dilute conditions. Furthermore, the reaction is
bioorthogonal, with neither reactants nor products reacting with any species endogenous to the
body. Only two years later, this work was adopted by Drs. Rafaella Rossin and Mark Robillard
to perform the first pretargeted SPECT imaging using the CC49-TCO immunoconjugate
targeting the TAG72 antigen.15 The radioligand used was a Tz-bearing DOTA derivative labeled
with

111

In, injected 24 h after administration of CC49-TCO.

These first experiments

demonstrated with remarkable clarity the benefits of pretargeting and the role that the Tz/TCO
reaction can play with cancer imaging, demonstrating specific uptake of radiotracer at the tumor
with excellent tumor:background ratios at 24 h following injection.

Figure 1.3: Inverse electron demand Diels-Alder reaction between Tz and TCO.

The use of Tz/TCO pretargeting was first adapted to PET imaging by the labs of
Weissleder and Lewis, using a [64Cu]Cu-NOTA-Tz and huA33-TCO.16 This work diverged
from the Tz originally proposed by Blackman et al., utilizing a new benzylamine-modified Tz
that exhibited greater water and serum stability, while maintaining exceptional rate kinetics
(>30,000 M-1s-1).17

Though the radioligand exhibited intestinal clearance, clear tumor

delineation was observable with little activity in non-target tissue (Figure 2.1). Additionally, a
comparison dosimetry study between a traditional, directly-labeled radioimmunoconjugate

7

([89Zr]Zr-DFO-huA33)

and

the

pretargeted

system

(huA33-TCO/[64Cu]Cu-NOTA-Tz)

demonstrated a 30-fold reduction in effective dose when using pretargeting.
This study demonstrated that pretargeted PET imaging is not only effective for cancer
imaging; it also has the capacity to significantly decrease the radiological burden to patients.
The dissertation to follow builds from the groundwork laid by Zeglis et al. to optimize the
Tz/TCO pretargeting methodology. It begins with the improvement of the pharmacokinetics and
clearance of the Tz-bearing radioligand. Next, the antibody is enzymatically modified to sitespecifically bear TCO moieties in an effort to produce better-defined immunoconjugates. A
novel TCO-bearing ligand is developed in an effort to improve radioligand binding to the
antibody. Finally, we take the first step towards clinical translation by initiating a trial of a boneseeking agent for pretargeting in dogs with osteosarcoma. Other chapters will include a novel
pretargeting system using leucine zippers and PET imaging using peptide amphiphile
nanoparticles.
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Chapter 2: Development of a Novel Radioligand for Pretargeted
PET Imaging
Disclaimer: This chapter was reproduced in part with permission from:
B.M. Zeglis, C. Brand, D. Abdel-Atti, K.E. Carnazza, B.E. Cook, S. Carlin, T. Reiner,
J.S. Lewis, Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma
via the Modulation of Radioligand Pharmacokinetics, Molecular Pharmaceutics, 12 (2015)
3575-3587. American Chemical Society.

2.1 Introduction
The first pretargeted PET imaging strategy was published by the labs of Weissleder and
Lewis and demonstrated effective tumor delineation in a subcutaneous xenografted mouse model
of colorectal cancer.16 While the method was highly effective in reducing effective dose nearly
30-fold, it was found that unbound radioligand, Tz-NOTA (Figure 2.2A), would clear slowly
through the intestines, effectively hampering its utility for colorectal cancer imaging (Figure
2.1). For this reason, it was necessary to optimize the pharmacokinetic profile of the Tz-bearing
radioligand. We set off to try two different methods. The first approach involved selection of a
sarcophagine-derived radiometal chelator (SarAr) to replace NOTA, as it has been shown that
alteration of charge and coordination environment can impact pharmacokinetics (Figure 2.2C).1821

The second method was the addition of a polyethylene glycol (PEG) linker between Tz and

NOTA. As it has been demonstrated extensively that the addition of PEG can drive renal
clearance and reduce background organ uptake, the original radioligand was modified to
[64Cu]Cu-NOTA-PEG7-Tz (Figure 2.2B).22-24

This chapter will focus on the synthesis,
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characterization, and testing of this [64Cu]Cu-SarAr-Tz radioligand, though comparisons to the
NOTA derivatives will be made throughout.

Figure 2.1: PET images of [64Cu]Cu-NOTA-Bn-Tz/A33-TCO pretargeting strategy. This
research was originally published in JNM. Brian M. Zeglis et al. J Nucl Med 2013;54:13891396.16

2.2 System Design
There are a number of studies illustrating that different charges on radiometal chelators
can significantly impact their pharmacokinetics, with differences in clearance profiles seen
between positively and negatively charged radiometal chelates.18-21, 25 It is for this reason that
the chelator SarAr was chosen to replace NOTA in the Tz-bearing radioligand, as SarAr serves
to drastically shift the overall charge of the ligand from -1 (CuII-NOTA) to +2 (CuII-SarAr)
(Figure 2.2).
We tested our pretargeting methodology on a model system of colorectal cancer,
targeting the A33 antigen. The A33 antigen is a transmembrane glycoprotein that is expressed in
>95% of colorectal cancers and can be effectively targeted using the fully humanized antibody
10

huA33.26, 27 When bound by huA33, A33 antigen expressed on malignant cells are persistent and
are neither internalized nor shed – an important feature for subsequent pretargeting injections.28
Interestingly, clinical trials of radiolabeled huA33 demonstrated that, while A33 antigen is also
expressed on healthy intestinal epithelial tissue, it is shed in its entirety over the course of a
week.29, 30 Therefore, while injections of huA33 exhibit binding on healthy tissue as well, the
only site of persistent A33 presentation is at the site of the tumor.

Figure 2.2: Tetrazine-bearing radioligands for pretargeted PET imaging. A) [64Cu]Cu-NOTA-Tz;
B) [64Cu]Cu-NOTA-PEG7-Tz; C) [64Cu]Cu-SarAr-Tz.

2.3 Materials and Methods
2.3.1 Synthesis

of

N1-(4-(((pivaloyloxy)amino)methyl)benzyl)-3,6,10,13,16,19-

hexaazabicyclo[6.6.6]icosane-1,8-diamine (SarAr-Bn-NHBoc)
N-Boc-4-(bromomethyl)-benzylamine (0.037 g; 0.12 mmol; 1.3 equiv.; 300.2 g/mol) was
added to a stirred solution of DiAmSar (0.030 g; 0.094 mmol; 1.0 equiv.; 314.5 g/mol) in
anhydrous dimethylformamide (4.0 mL) at room temperature (Figure 2.3). Sodium carbonate
(0.034 g; 0.32 mmol; 3.5 equiv.; 105.9 g/mol) was added, and the reaction solution was stirred at
70 °C for 16 h. The reaction was diluted with water (6.0 mL), and purification by HPLC
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(3.0 mL/min, 5% to 80% CH3CN in 15 min) afforded SarAr-Bn-NHBoc (MW = 533.8; 0.035 g;
70%) as a colorless solid: tR = 9.4 min. 1H NMR (500 MHz, DMSO), δ, ppm: 7.38-7.50 (m, 4H),
4.18 (m, 2H), 2.31-3.98 (m, 42H), 1.35 (s, 9H). ESI-MS(+): m/z = 534.5 [M+H]+. HRMS (ESI):
m/z calcd. for C27H52N9O2: 534.4244; found: 534.4250.

2.3.2 Synthesis of N1-(4-(aminomethyl)benzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane1,8-diamine (SarAr-Bn-NH2)
Trifluoroacetic acid (TFA) (2.0 mL) was added slowly to a stirred solution of SarAr-BnNHBoc (0.031 g; 0.058 mmol; 1.0 equiv.; 533.4 g/mol) in dry acetonitrile (2.0 mL), and the
reaction mixture was stirred at room temperature for 90 min. Evaporation of the solvents under
reduced pressure and purification by HPLC (6.0 mL/min, 5% to 60% CH3CN in 20 min)
afforded SarAr-Bn-NH2 (MW = 434.7; 0.026 g, 99%) as a colorless solid: tR = 6.8 min. 1H NMR
(500 MHz, DMSO), δ, ppm: 7.55 (d, 2H), 7.51 (d, 2H), 4.23 (s, 2H), 2.56-4.05 (m, 27H).
ESI-MS(+): m/z = 434.4 [M+H]+. HRMS (ESI): m/z calcd. for C22H44N9: 434.3720; found:
434.3715.

2.3.3 Synthesis

of

N1-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-N5-(4-(((8-amino-3,6,10,13,16,19-

hexaazabicyclo[6.6.6]icosan-1-yl)amino)methyl)benzyl)glutaramide (Tz-SarAr)
A solution of Tz-NHS (5.0 mg; 0.013 mmol; 1.0 equiv.; 398.4 g/mol) in anhydrous
dimethylformamide (400 µL) was added to a stirred solution of SarAr-Bn-NH2 (5.4 mg;
0.013 mmol; 1.0 equiv.; 434.7 g/mol) in anhydrous dimethylformamide (200 µL) at room
temperature, and the reaction solution was stirred in the dark for 2 h at room temperature. After
12

dilution with water (1.8 mL), purification by HPLC (1.0 mL/min, 5% to 80% CH3CN in 15 min)
afforded Tz-SarAr (MW = 716.9; 3.9 mg; 42%) as a pink solid: tR = 9.5 min. 1H NMR
(600 MHz, D2O), δ, ppm: 10.25 (s, 1H), 8.31 (d, 2H), 7.46 (d, 2H), 7.22-7.27 (m, 4H), 4.39 (m,
2H), 4.24 (m, 3H), 2.46-3.95 (m, 24H), 2.41-2.44 (m, 4H), 1.83 (m, 2H). ESI-MS(+): m/z =
717.6 [M+H]+. HRMS (ESI): m/z calcd. for C36H57N14O2: 717.4789; found: 717.4788.

Figure 2.3: Synthesis of Tz-SarAr.

2.3.4 Preparation of [64Cu]Cu-SarAr-Tz
A solution of Tz-SarAr (5-25 µg; 6.9-34.9 nmol) in NH4OAc buffer (0.2 M, pH 5.5, 200
µL) was first prepared. Then, the desired amount of [64Cu]CuCl2 in 0.1 M HCl (1500-7500 µCi)
was added to the reaction mixture, and the solution was placed on an agitating thermomixer at
300 rpm for 30 minutes at room temperature. After this incubation, the [64Cu]Cu-SarAr-Tz was
purified via reverse phase C18 HPLC (tR = 8.7 min) to yield the completed radioligand in >99%
13

radionuclidic purity, 79  7% decay-corrected isolated yield, and a specific activity of 398  46
µCi/µg (310  36 mCi/µmol; 14.7  1.3 GBq/µmol) (n = 6).

2.3.5 Preparation of huA33-TCO
HuA33 (2 mg, 13.3 nmol) was dissolved in 500 L of phosphate buffered saline (PBS,
pH 7.4), and the pH of the solution was adjusted to 8.8-9.0 with NaHCO3 (0.1 M). To this
solution was added an appropriate volume of TCO-NHS in DMF (10 mg/mL) to yield a TCONHS:huA33 reaction stoichiometry of 10:1. The resulting solution was incubated with gentle
shaking for 30 min at room temperature. After 30 min, the modified antibody was purified using
size-exclusion chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare; dead volume
= 2.5 mL, eluted with 500 mL fractions of PBS, pH 7.4) and concentrated with centrifugal
filtration units with a 50,000 molecular weight cut off (AmiconTM Ultra 4, Millipore Corp.,
Billerica, MA) and PBS (pH 7.4).

2.3.6 Pretargeted PET Imaging Experiments
All pretargeted PET imaging experiments were performed on an Inveon PET/CT scanner
(Siemens Healthcare Global). Female athymic nude mice (n = 5) bearing subcutaneous SW1222
(right shoulder) xenografts (100-150 mm3, 9-12 days post-inoculation) were administered 100 g
(0.66 nmol) huA33-TCO (in 200 L 0.9% sterile saline) via intravenous tail vein injection. After
an accumulation interval of 24 h the same mice were then administered [64Cu]Cu-SarAr-Tz (400450 Ci, 0.66 nmol in 200 L 0.9% sterile saline) and PET/CT images were acquired 4, 12, and
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24 h after injection of radiotracer (Figure 2.4). The images stand in stark contrast to those
obtained with [64Cu]Cu-NOTA-Tz, as no intestinal clearance can be seen. The tumors are
clearly delineated and any background uptake is limited to the blood pool with only a small
amount present in the kidneys. One mouse can be seen with activity in the bladder as well,
confirming renal clearance of the radiotracer. It is interesting to note that uptake in the tumor is
also higher in mice administered [64Cu]Cu-SarAr-Tz (7.4 ± 2.0% ID/g) than those given
[64Cu]Cu-NOTA-Tz (4.0 ± 0.9% ID/g).16

Figure 2.4: Pretargeted PET imaging of athymic nude mice bearing SW1222 xenografted tumors
on their right shoulder. Mice were administered 100 µg of huA33-TCO followed 24 h later by
500 µCi of [64Cu]Cu-SarAr-Tz. Images were taken 4, 12, and 24 h following injection of
radioligand. Clear tumor delineation can be seen with concurrent clearance from background
tissues. PET/CT was obtained at 24 h and provides anatomical reference for tumor location.

2.3.7 Pretargeted Biodistribution Experiments
Female athymic nude mice bearing subcutaneous SW1222 (right shoulder) xenografts
(100-150 mm3, 9-12 days post-inoculation) were administered 100 g (0.66 nmol) huA33-TCO
15

(in 200 L 0.9% sterile saline) via intravenous tail vein injection. After an accumulation interval
period of 24 h the same mice were then administered [64Cu]Cu-SarAr-Tz (300-350 Ci in 200
L 0.9% sterile saline), also via intravenous tail vein injection. Animals (n = 4 per group) were
euthanized by CO2(g) asphyxiation at 1, 4, 12, and 24 h after injection. After asphyxiation,
tissues were removed, rinsed in water, dried in air for 5 min, weighed, and counted in a gamma
counter calibrated for

64

Cu. Counts were converted into activity using a calibration curve

generated from known standards. Count data were background- and decay-corrected to the time
of injection, and the percent injected dose per gram (%ID/g) for each tissue sample was
calculated by normalization to the total activity injected (Figure 2.5).

Figure 2.5: Comparison biodistributions of [64Cu]Cu-SarAr-Tz and [64Cu]Cu-NOTA-Tz*.
Pretargeted biodistribution of athymic nude mice bearing SW1222 xenografted tumors (n=4).
Mice were administered 100 µg of huA33-TCO followed 24 h later by 500 µCi of Tzradioligand. They were sacrificed and organs harvested at 1, 4, 12, and 24 h post-administration
of activity. *Data originally reported in Zeglis, B. M. et al. Journal of Nuclear Medicine. 54,
1389−1396 (2013). ©2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.16
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It can be seen that activity in the blood continues to decrease over the time points
gathered, with the lowest being 2.6 ± 0.2% ID/g. Concurrently, the activity in the tumor rises
over the course of 24 h, reaching a maximum of 7.4 ± 2.0% ID/g. This suggests that, while most
of the in vivo clicking of radioligand to the antibody is occurring at the tumor, there is still some
circulating antibody that clicks to radioligand in the blood before binding the tumor. The
kidneys have higher uptake than most other background organs (2.0 ± 0.2% ID/g at 24 h),
suggesting that the radioligand [64Cu]Cu-SarAr-Tz accumulates there to a small degree.
Importantly, the large intestine (0.26 ± 0.1% ID/g) and liver (1.5 ± 0.2% ID/g) have very low
activity relative to that of the tumor after 24 h. As the sites of primary and secondary disease
respectively in colorectal cancer it is crucial to have high contrast in these tissues.

2.4 Conclusion
In setting out to eliminate gut clearance of our Tz-radioligand it is difficult to imagine a
better outcome than that achieved with Tz-SarAr. The effect of charge on clearance route is
apparent, with a drastic shift from intestinal excretion with the negatively charged CuII-NOTATz (-1) to urinary excretion with the positively charged Cu II-SarAr-Tz (+2). There is a plethora
of literature to support this finding that positively charged species often clear renally, though
there are of course other complex factors that are at play as well.18 For instance, Tz-PEG7NOTA ultimately served to reduce intestinal clearance, but not eliminate it altogether. For this
reason, of the three Tz-bearing radioligands, [64Cu]Cu-SarAr-Tz was the clear winner with
exceptional in vivo performance. It serves as the primo radioligand for the remainder of this
thesis where the IEDDA reaction is utilized for pretargeting. Furthermore, it has been the
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subject of a successful pathology/toxicology study and is slated for use in an upcoming clinical
trial of pretargeting.
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Chapter 3: Pretargeted PET Imaging Using a Site-Specifically
Modified Immunoconjugate
Disclaimer: The following text was reproduced in full with permission from:
Cook, B. E.; Adumeau, P.; Membreno, R.; Carnazza, K. E.; Brand, C.; Reiner, T.;
Agnew, B. J.; Lewis, J. S.; Zeglis, B. M., Pretargeted PET Imaging Using a Site-Specifically
Labeled Immunoconjugate. Bioconjugate Chemistry 2016, 27 (8), 1789-1795. American
Chemical Society.

3.1 Introduction
The use of radiolabeled antibodies for the non-invasive imaging of cancer biomarkers
stands poised to be a vital component in the emerging era of personalized medicine.5 Yet despite
this promise, a number of important obstacles stand in the way of the widespread clinical
implementation of radioimmunoconjugates. Indeed, from a bioconjugation standpoint, two
especially troublesome issues stand out. First, the relatively long biological half-life of antibodies
mandates the use of radioisotopes with comparable physical half-lives, for example

89

Zr (t1/2 ~

3.2 d) or 124I (t1/2 ~ 4.2 d).31-33 Not surprisingly, this exigency can lead to high radiation doses to
the healthy organs of the patient.34-40 Second, traditional methods of antibody modification rely
on the covalent coupling of amine-reactive probes to lysine residues within the antibody.
However, due to the presence of multiple lysines on the surface of immunoglobulins, controlling
the location and frequency of these couplings is impossible. This non-site-specific approach to
bioconjugation can yield poorly defined and heterogeneous immunoconjugates that suffer from
suboptimal in vivo behavior.41-47
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In recent years, significant effort from an array of research groups has been dedicated to
addressing these concerns through the development of novel approaches to pretargeted imaging
and site-specific bioconjugation.41,

43-46

Our laboratories have contributed two different

methodologies based on bioorthogonal chemistry.48-52 First, in order to counter the dosimetric
limitations of traditional radioimmunoconjugates, we have created a pretargeted PET imaging
approach that leverages the extraordinarily rapid inverse electron-demand Diels-Alder
cycloaddition between tetrazine (Tz) and trans-cyclooctene (TCO) (Figure 3.1).53-55 This method
has four straightforward steps: (1) the injection of a TCO-modified antibody; (2) the
accumulation of the TCO-labeled antibody at the tumor and its simultaneous clearance from the
blood; (3) the injection of a small molecule Tz-bearing radioligand; and (4) the in vivo click
ligation between the two components followed by clearance of any excess radioligand (Figure
1.1). Importantly, in murine models of both colorectal and pancreatic cancer, we have shown that
this strategy delineates tumor tissue with excellent image contrast at only a small fraction of the
radiation dose to healthy tissues created by traditional immunoconjugates.16, 50-52

Figure 3.1: The reaction between tetrazine and trans-cyclooctene as it occurs in vivo.

We turned to a different bioorthogonal reaction — the strain-promoted azide-alkyne
cycloaddition (SPAAC) — in our effort to improve upon the site-specificity of traditional
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bioconjugation techniques.53,

56

We developed a robust and modular chemoenzymatic strategy

for the site-specific modification of antibodies on the heavy chain glycans, the conserved
biantennary oligosaccharide chains located on the CH2 regions of immunoglobulins (Figure
3.2).48,

57

This approach relies on the enzymatic activity of β-1,4-galactosidase and a

promiscuous galactosyltransferase [Gal-T(Y289L)] for the incorporation of azide-modified
monosaccharides — GalNAz — into the sugar chains. The resulting azide-modified antibody can
then be easily conjugated to any dibenzocyclooctyne-bearing cargo via the SPAAC ligation. In
three different murine model systems, we have illustrated that this approach produces welldefined and homogenous immunoconjugates with in vivo behavior comparable to — and often
superior to — immunoconjugates synthesized using traditional, non-site-specific methods.57-59
In the work at hand, we have successfully combined these two methodologies to create a
pretargeted PET imaging strategy using a

64

Cu-labeled tetrazine radioligand and a site-

specifically conjugated antibody-TCO immunoconjugate. This approach yields clearly visualized
tumors with excellent tumor-to-background activity concentration ratios and produced organspecific and overall effective radiation doses far below those created by non-pretargeted
methodologies.

3.2 Results and Discussion
The starting point for this investigation was the optimized pretargeted PET imaging
methodology recently reported by our laboratory.16, 51 This system employs two components: a
positively charged 64Cu-labeled tetrazine radioligand ([64Cu]-SarAr-Tz) and a trans-cyclooctenebearing immunoconjugate of the huA33 antibody (huA33-TCO) (Figure 3.1). The huA33
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antibody targets the A33 antigen, a transmembrane glycoprotein that is expressed by >95% of
colorectal carcinomas and, critically, is not internalized or shed upon binding by the antibody. 27,
30, 60-64

This imaging approach clearly delineates antigen-expressing tumor tissue with high

tumor-to-background activity concentration ratios and very low radiation doses to healthy tissues
when compared with tradition immunoconjugation techniques.51 However, we contend there is
room for improvement, specifically by employing a more homogeneous and well-defined TCOmodified immunoconjugate synthesized via site-specific bioconjugation.

Figure 3.2. Chemoenzymatic site-specific synthesis of sshuA33-PEG12-TCO.

The site-specific modification of huA33 was performed using a three-step process that
leverages both enzymatic transformations and a second variety of bioorthogonal click chemistry
(Figure 3.2). First, the terminal galactose residues on the heavy chain glycans were removed via
incubation with β-1,4-galactosidase. Next, Gal-T(Y289L), a promiscuous galactosyltransferase,
was used to attach azide-modified sugars (GalNAz) to the termini of the sugar chains (see
22

Supporting Information).65-72 Finally, the azide-modified antibody was conjugated to a
dibenzocyclooctyne-bearing variant of TCO (DIBO-PEG12-TCO) via the strain-promoted azidealkyne cycloaddition to give the final product: sshuA33-PEG12-TCO.
The characterization of the

ss

huA33-PEG12-TCO was carried out to verify both the

number and placement of the PEG12-TCO moieties on the antibody.

MALDI-TOF mass

spectrometry analysis of sshuA33-PEG12-TCO revealed that the immunoconjugate was modified
with ~2.0 TCO/mAb, a result corroborated by separate experiments that used an AlexaFluorTM
680-modified tetrazine construct to determine the degree of labeling via UV-Vis
spectrophotometry. The site-specificity of the modification was confirmed via denaturing SDSPAGE analysis (Figure 3.3).

Figure 3.3: SDS-PAGE gel of (left to right) unmodified huA33, sshuA33-N3, and sshuA33PEG12-TCO. The red line indicates the molecular weight of the antibody heavy chain and
illustrates a shift in the MW of the heavy chain of the site-specifically modified
immunoconjugate. The black line, indicating the MW of the light chain, displays no shift upon
site-specific modification.
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In these experiments, a positive shift in the molecular weight of the heavy chain was
observed for sshuA33-PEG12-TCO compared to that of unmodified huA33, while no molecular
weight difference was observed between the light chains of the two constructs. The SDS-PAGE
analysis of immunoconjugates that had been treated with PNGaseF — an amidase that removes
the heavy chain glycans entirely — provided additional insight (Figure 3.4). In these assays, a
shift in molecular weight of the heavy chain could be observed in samples untreated by
PNGaseF, while no difference was observed in samples that were treated with PNGaseF. Taken
together, these electrophoresis experiments clearly illustrate that the bioconjugation of TCO was
specific not only to the heavy chain of the antibody but to the heavy chain glycans.

Figure 3.4: SDS-PAGE following treatment with PNGaseF (~40 kDa). Columns are (from left to
right) unmodified huA33, unmodified huA33 treated with PNGaseF, sshuA33-N3, sshuA33-N3
treated with PNGaseF, sshuA33-PEG12-TCO, and sshuA33-PEG12-TCO treated with PNGaseF. A
second set of sshuA33-PEG12-TCO both with and without PNGaseF treatment was included to
verify modification consistency. As with the gel in Figure 3.3, the red dotted line indicates the
molecular weight of the heavy chain and illustrates the shift in the heavy chain of the PEG12TCO-labeled immunoconjugate. The molecular weight of the heavy chain after enzymatic
cleavage is the same for all three constructs, clearly illustrating that the conjugation reaction
specifically modifies the heavy chain glycans.
24

As a final characterization step prior to in vivo experiments, the in vitro immunoreactivity
of sshuA33-PEG12-TCO was measured. To this end, sshuA33-PEG12-TCO was radiolabeled via
click ligation with [64Cu]Cu-SarAr-Tz, purified via size exclusion chromatography, and
incubated with a vast excess of A33 antigen-expressing SW1222 human colorectal carcinoma
cells. Using this antigen saturation technique, it was determined that the immunoconjugate
maintained a very high immunoreactive fraction of 0.94 ± 0.02, not surprising given that our sitespecific modification occurs on the CH2 domains of the Fc region, far from the antigen-binding
domains of the immunoglobulin.

Figure 3.5. Pretargeted PET imaging using sshuA33-PEG12-TCO (100 g), [64Cu]Cu-SarAr-Tz
(300-350 Ci), and a 24 h accumulation interval. (Left) Coronal slices demonstrating high
uptake in the tumor (white arrow); (center) maximum intensity-projections (MIP) showing
clearance from background organs; (right) a co-registered PET/CT scan obtained 24 h after the
administration of the radioligand.

Once fully characterized, the sshuA33-PEG12-TCO immunoconjugate was ready to be put
to the test in vivo. To this end, athymic nude mice bearing subcutaneous A33 antigen-expressing
SW1222 human colorectal carcinoma xenografts (5  106 cells; right shoulder; 16-18 days postinoculation) were used as a model system. These mice were first injected with sshuA33-PEG12TCO (0.66 nmol) and then — following a 24 h accumulation interval — [64Cu]Cu-SarAr-Tz
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(300-350 μCi; 0.66-0.77 nmol), and static PET scans were acquired 4, 12, and 24 h after the
administration of the radiotracer (Figure 3.5). These images clearly indicate that this pretargeting
approach quickly and effectively visualizes tumor tissue. As early as four hours post-injection,
the tumor tissue is clearly delineated. Critically, image contrast improves with time as the excess
radioligand is cleared via the urinary tract. Indeed, by 24 h p.i. the only tissue displaying
appreciable uptake of the radiotracer is the tumor, with only minimal background signal
remaining in healthy organs.
An acute biodistribution experiment was performed in an effort to more accurately
quantify

the

in

vivo

behavior

of

the

pretargeting

system

(

Figure 3.6). The biodistribution was performed under conditions identical to the PET experiment
and largely corroborated the imaging results. As in the PET data, significant tumor uptake can be
observed in the first hour post-injection (6.7 ± 1.7 %ID/g) and increased over the course of the
experiment, ultimately reaching 11.2 ± 2.4 %ID/g at 24 h p.i.. Conversely, the activity
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concentration in the blood pool followed an opposite trajectory, starting at 9.5 ± 1.6 %ID/g at 1 h
p.i. and decreasing until it reached 4.0 ± 0.7 %ID/g at 24 h p.i. This trend of clearance is
mirrored — though at significantly lower activity concentration levels — in nearly all other
organs sampled, including the heart, lungs, liver, and kidneys. Of these, the kidneys
demonstrated the highest non-target uptake, with 2.7 ± 0.1 %ID/g at 24 h p.i. Two critical
metrics for evaluating the efficacy of sshuA33-PEG12-TCO are the tumor-to-large intestine and
tumor-to-liver ratios, as these organs represent the most clinically relevant background tissues
for primary and metastatic disease, respectively.

The tumor-to-large intestine ratio was

exceptional, (18.0 ± 5.2 at 24 h p.i.) while the liver was slightly lower (5.2 ± 1.4 at 24 h p.i.) but
still quite promising.

Figure 3.6. Biodistribution of pretargeting using sshuA33-PEG12-TCO (0.66 nmol), 64Cu-Tz-Sar
(300-350 Ci; 0.66-0.77 nmol), and a 24 h accumulation interval in athymic nude mice bearing
A33 antigen-expressing SW1222 colorectal carcinoma xenografts.
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In an effort to decrease the residual levels of activity in the blood, an additional
pretargeted biodistribution study was performed using a longer accumulation interval of 48 h
(Figure 3.7). As expected, the use of a prolonged accumulation interval decreased activity
concentrations in the blood, a result that almost certainly stems from reducing the amount of
ss

huA33-PEG12-TCO remaining in the blood at the time of the injection of the radioligand and

thus concomitantly reducing the amount of

64

Cu-labeled huA33 that is formed through click

ligations within the blood pool. However, the use of a 48 h accumulation interval also resulted in
small reductions to the amount of uptake in the tumor, a phenomenon possibly related to the
slow in vivo isomerization of reactive TCO to unreactive cis-cyclooctene. Clearly, as in all
pretargeting approaches, the accumulation interval must be carefully tailored to strike the
important but delicate balance between tumor and healthy organ activity concentrations. Finally,
it is important to note that in vivo experiments performed in previous investigations using
[64Cu]Cu-Tz-SarAr alone, pretargeting with a non-specific isotype control IgG, or pretargeting
with an unmodified huA33 construct have been shown to yield minimal (<1.5 %ID/g) tumoral
activity concentrations.16
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Figure 3.7: Biodistributions of sshuA33-PEG12-TCO comparing 24 (blue) versus 48 h (orange)
accumulation intervals.

Importantly, control biodistribution studies were performed using huA33 non-sitespecifically labeled with TCO-NHS (nshuA33-TCO) and huA33 non-site-specifically labeled
with TCO-PEG12-NHS (nshuA33-PEG12-TCO) (Figure 3.8). To this end, athymic nude mice
bearing SW1222 xenografts were injected with

ns

huA33-TCO or

ns

huA33-PEG12-TCO (0.66

nmol), injected with [64Cu]Cu-SarAr-Tz (300-350 Ci; 0.66-0.77 nmol) after an accumulation
interval of 24 h, and sacrificed either 4 or 24 h after the administration of the radioligand (Figure
3.9). Importantly, the tumor and healthy organ activity concentrations obtained with all three
immunoconjugates were very similar.
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Figure 3.8: Synthetic scheme for the non-site-specific labeling of huA33 with PEG12-TCO (top)
and non-PEGylated TCO (bottom).

Interestingly, however, the activity concentration remaining in the blood using sshuA33PEG12-TCO (3.96 ± 0.72 %ID/g at 24 h p.i.) was higher than that measured using nshuA33-TCO
(2.42 ± 0.76 %ID/g at 24 h p.i.) or nshuA33-PEG12-TCO (3.11 ± 0.49 %ID/g at 24 h p.i.). While
the origins of this phenomenon are unclear, it may stem from an increase in the blood-half-life of
ss

huA33-PEG12-TCO related to the presence of the bulky DIBO and PEG12 moieties. On the

whole, however, these data clearly underscore that this pretargeting strategy reaps the critical
benefits of site-specific bioconjugation  i.e. increased homogeneity and the use of betterdefined immunoconjugates  without significantly compromising in vivo performance.
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Figure 3.9: A comparison of the biodistribution data for pretargeting using a 24 h accumulation
interval, [64Cu]Cu-SarAr-Tz, and non-site-specifically labeled huA33-TCO (NS-TCO), huA33PEG12-TCO (NS-PEG), or sshuA33-PEG12-TCO (SS-PEG).

Moving on, it was important to verify that the in vivo click reaction — and not simply the
non-specific localization of [64Cu]Cu-SarAr-Tz — was responsible for the strategy’s effective
delineation of tumor tissue. To this end, at the conclusion of the imaging studies, representative
tumors were resected, and slices were made for autoradiographic and immunohistological
analysis (Figure 3.10). Comparison of the hematoxylin and eosin (H&E) stain with the
immunofluorescence staining for huA33 clearly shows that the huA33 construct associates only
with tumor cells and not vasculature, stroma, or areas of necrosis. Perhaps even more
importantly, there is significant overlap between areas of high huA33 density and increased
activity from the autoradiograph image, illustrating the co-localization of 64Cu and huA33. This
suggests that we have achieved both the specific binding of huA33 to A33 antigen and the
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successful in vivo ligation of radioligand to antibody. The localization of the huA33 can also be
seen to occur on the outside of the cells, further corroborating surface persistence of the huA33A33 antigen immunocomplex.

Figure 3.10: Histological staining and autoradiography of a resected tumors. Autoradiography
(A), huA33 immunofluorescence staining using an anti-human AlexaFluorTM-568 counterstain
(B), overlay of A and B illustrating the co-localization of the autoradiography and
immunofluorescence signals, and hematoxylin and eosin histology staining (D).

Finally, the biodistribution data obtained with [64Cu]Cu-SarAr-Tz and sshuA33-PEG12TCO were used to perform dosimetry calculations for the pretargeted PET imaging approach. To
this end, activity curves were constructed using results from the biodistribution data, and then
integrated to provide time-activity data for each organ. The OLINDA computer program was
then used to determine the mean organ absorbed doses and effective dose for the methodology
(Figure 3.11).
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Target Organ
Adrenals
Brain
Breasts
Gallbladder Wall
Lower Lg. Intestine Wall
Small Intestine
Stomach Wall
Upper Lg. Intestine Wall
Heart Wall
Kidneys
Liver
Lungs
Muscle
Ovaries
Pancreas
Red Marrow
Osteogenic Cells
Skin
Spleen
Testes
Thymus
Thyroid
Urinary Bladder Wall
Uterus
Total Body
Effective Dose Equivalent***

ss

huA33-PEG 12-TCO

Pretargeting
Non-site-specific labeling
64
Cu-Tz-SarAr* 64Cu-Tz-NOTA** 89Zr-DFO-huA33**

0.0737
0.071
0.064
0.0766
0.0791
0.0923
0.076
0.0776
0.0873
0.0832
0.0666
0.0713
0.043
0.0776
0.0776
0.0706
0.188
0.0585
0.0745
0.0687
0.0696
0.07
0.0777
0.0804
0.0766
0.0791

0.0374
0.0364
0.0325
0.0393
0.0484
0.042
0.0471
0.0411
0.0429
0.066
0.0301
0.0325
0.0193
0.0404
0.0391
0.0302
0.0897
0.0298
0.0146
0.0348
0.0351
0.0354
0.0394
0.0413
0.038
0.0414

0.0251
0.0236
0.0209
0.0272
0.166
0.033
0.0267
0.114
0.0294
0.0315
0.0311
0.0289
0.0138
0.0299
0.0258
0.053
0.0852
0.0194
0.018
0.0225
0.0227
0.0228
0.0262
0.0277
0.0272
0.046

1.64
0.764
0.621
1.44
1.34
1.11
0.949
1.2
1.55
2.53
2.84
2.26
1.27
1.09
1.37
3.12
6.09
0.677
2.52
0.683
0.988
0.947
0.826
0.941
1.39
1.54

Figure 3.11: Dosimetry calculated from biodistribution experiments.. Absorbed doses in
rad/mCi. *Data from Zeglis, B.M., et al., Mol. Pharm., (2015)51, **Data from Zeglis, et al., J.
Nucl. Med., 54, 1389-1396 (2013)16, ***Effective dose equivalent in rem/mCi.

The effective dose for pretargeting with [64Cu]Cu-SarAr-Tz and sshuA33-PEG12-TCO
was 0.079 rem/mCi, which compares favorably to that of the non-site-specific pretargeting
approach (0.041 rem/mCi) previously reported.51 The slightly higher absorbed dose for this sitespecific system is most likely due to the addition of the bulky DIBO moieties and hydrophilic
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PEG12 chains, which can increase circulation times and thus increase uptake and retention in
healthy organs. Finally, the effective dose of sshuA33-PEG12-TCO is nearly 20-times lower than
that produced by directly-labeled 89Zr-DFO-huA33.16

3.3 Conclusion
In the preceding pages, we have reported the development of a site-specifically labeled
huA33-TCO immunoconjugate for the pretargeted PET imaging of colorectal cancer. Our
approach quickly and clearly delineated tumors with both high tumor-to-healthy tissue activity
concentration ratios and low dose rates to healthy tissues. Importantly, the uptake and dosimetry
data for the site-specifically labeled sshuA33-PEG12-TCO construct are comparable to — and in
some cases, superior to — that obtained with analogous, non-site-specifically labeled
immunoconjugates. Furthermore, both the bioorthogonal pretargeting strategy and the sitespecific modification approach are highly modular: both techniques can be applied to any tumortargeting immunoglobulin for a wide variety of applications. Ultimately, our approach facilitates
pretargeted PET imaging with a well-defined and homogenous immunoconjugate, an advance
that will help to expedite the clinical translation of future pretargeting strategies.

3.4 SUPPLEMENTAL: Materials and Methods
Instrumentation: All instruments were calibrated and maintained in accordance with
standard quality-control procedures. UV-Vis measurements were taken on a Shimadzu BioSpecNano Micro-Volume UV-Vis Spectrophotometer (Shimadzu, Kyoto, Japan). Activity
measurements were made using a Capintec CRC-15R Dose Calibrator (Capintec, Ramsey, NJ).
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Biodistribution samples were counted for activity for 1 min on a calibrated Perkin Elmer
(Waltham, MA) Automatic Wizard Gamma Counter. Radiolabeling of the [64Cu]Cu-SarAr-Tz
radioligand was monitored using silica-gel impregnated glass-fiber instant thin-layer
chromatography paper (Pall Corp., East Hills, NY) and analyzed on a Bioscan AR-2000 radioTLC plate reader using Winscan Radio-TLC software (Bioscan Inc., Washington, D. C.).
HPLC: HPLC purifications (Buffer A: 0.1% TFA in water, Buffer B: 0.1% TFA in
CH3CN) were performed on a Shimadzu UFLC HPLC system equipped with a DGU-20A
degasser, a SPD-M20A UV detector, two LC-20AP pump systems, a CBM-20A communication
BUS module, and a FRC-10A fraction collector using a reversed-phase C18 XTerra® Preparative
MS OBDTM column (10 μm, 19.2 mm × 250 mm; 10 mL/min) or a reversed-phase C18 semi-Prep
Phenomenex® Jupiter column (5 μm, 10 mm × 250 mm; 2 mL/min). Analytical HPLC runs were
performed using a reversed-phase C18 Phenomenex® Jupiter column (5 μm, 4.6 mm × 250 mm;
1 mL/min). All radio-HPLC analyses and purifications were performed using a Shimadzu HPLC
equipped with a reversed-phase C18 column (Phenomenex Luna analytical 4.6 x 250 mm; 1
mL/min), 2 LC-10AT pumps, a SPD-M10AVP photodiode array detector, and a Bioscan Flow
Counts radioactivity detector with a gradient of 5:95 CH3CN:H2O (both with 0.1% TFA) to 95:5
CH3CN:H2O over 15 min.

3.4.1 Preparation of nshuA33-TCO
HuA33 (1.6 mg, 10.7 nmol) provided by the Ludwig Institute was dissolved in 500 L of
phosphate buffered saline (PBS, pH 7.4), and the pH of the solution was adjusted to 8.8-9.0 with
Na2CO3 (0.1 M). An appropriate volume of TCO-NHS in DMF (12.5 mg/mL) was added to yield
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a TCO-NHS:huA33 reaction stoichiometry of 20:1. The resulting solution was incubated at room
temperature for one hour with shaking at 300 rpm. After 1 hour, the modified antibody was
purified using size-exclusion chromatography (Sephadex G-25M, PD-10 column, GE
Healthcare; dead volume = 2.5 mL, eluted with 2 mL fractions of PBS, pH 7.4) and concentrated
with centrifugal filtration units with a 50,000 molecular weight cut off (AmiconTM Ultra 2mL,
Millipore Corp., Billerica, MA) and PBS (pH 7.4).

3.4.2 Preparation of nshuA33-PEG12-TCO
HuA33 (1.6 mg, 10.7 nmol) was dissolved in 500 L of phosphate buffered saline (PBS,
pH 7.4), and the pH of the solution was adjusted to 8.8-9.0 with Na2CO3 (0.1 M). To this
solution, a volume of TCO-PEG12-NHS in DMF (25 mg/mL) was added to yield a TCO-PEG12NHS:huA33 reaction stoichiometry of 6:1. The resulting solution was incubated at room
temperature for one hour with shaking at 300 rpm. After 1 hour, the modified antibody was
purified using size-exclusion chromatography (Sephadex G-25 M, PD-10 column, GE
Healthcare; dead volume = 2.5 mL, eluted with 2 mL fractions of PBS, pH 7.4) and concentrated
with centrifugal filtration units with a 50,000 molecular weight cut off (AmiconTM Ultra 2mL,
Millipore Corp., Billerica, MA) and PBS (pH 7.4).

3.4.3 Site-Specific Synthesis of sshuA33-PEG12-TCO
Glycan Modification: huA33 (2.5 mg, 9.75 mg/mL, in phosphate buffered saline [PBS],
pH 7.4) was buffer exchanged into antibody preparation buffer (50 mM Bis-Tris, 100 mM NaCl,
pH 6.0) using centrifugal filtration units with a 50,000 molecular weight cut off (Amicon TM Ultra
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0.5 mL, Millipore Corp., Billerica, MA). Following buffer exchange, the antibody (2.5 mg in 120
L of antibody preparation buffer) was combined with β-1,4-galactosidase (from S. pneumonia
[2 mU/μL], obtained from ProZyme, Inc., Hayward, CA) and incubated for 6 hours at 37 °C.
GalNAz Labeling: After 6 hrs, the modified antibody sample was then combined with
UDP-GalNAz (10 μL of a 40 mM solution in H2O), MnCl2 (2.5 μL of a 1 M solution), Tris
buffer (12.5 μL of a 1 M solution (pH 7.0)), Gal-T(Y289L) [80 μL of 0.29 mg/mL in 50mM Tris,
5 mM EDTA (pH 8.0)] and H2O (65 μL) and was incubated for 16 h at 30 °C. The following
day, the GalNAz-modified antibodies were isolated using centrifugal filtration units with a
50,000 molecular weight cut off (AmiconTM Ultra 0.5 mL, Millipore Corp., Billerica, MA) and
then buffer-exchanged into tris-buffered saline (TBS; 0.05 M tris-HCl, 0.15 M NaCl).
DIBO-PEG12-TCO Ligation: The purified GalNAz-modified antibody was then
combined with 200 L of DIBO-PEG12-TCO (2 mM in DMSO) and incubated at 25 °C
overnight. The following day, the completed immunoconjugate was purified via size exclusion
chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare) and concentrated using
centrifugal filtration units with a 50,000 molecular weight cut off (AmiconTM Ultra 2 mL,
Millipore Corp., Billerica, MA) and phosphate buffered saline (PBS, pH 7.4).

3.4.4 Synthesis

of

N1-(4-(1,2,4,5-tetrazin-3-yl)benzyl)-N5-(4-(((8-amino-3,6,10,13,16,19-

hexaazabicyclo[6.6.6]icosan-1-yl)amino)methyl)benzyl)glutaramide (Tz-SarAr)
Tz-SarAr was synthesized according to previously published protocols.51 To summarize,
a solution of Tz-NHS (5.0 mg; 0.013 mmol; 1.0 equiv.; 398.4 g/mol) in anhydrous
dimethylformamide (400 µL) was added to a stirred solution of SarAr-Bn-NH2 (5.4 mg;
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0.013 mmol; 1.0 equiv.; 434.7 g/mol) in anhydrous dimethylformamide (200 µL) at room
temperature, and the reaction solution was stirred in the dark for 2 h at room temperature. After
dilution with water (1.8 mL), purification by HPLC (1.0 mL/min, 95:5 H2O:CH3CN to 20:80
H2O:CH3CN over 15 min) afforded Tz-SarAr (MW = 716.9; 3.9 mg; 42%) as a pink solid:
tR = 9.5 min. 1H NMR (600 MHz, D2O), δ, ppm: 10.25 (s, 1H), 8.31 (d, 2H), 7.46 (d, 2H), 7.227.27 (m, 4H), 4.39 (m, 2H), 4.24 (m, 3H), 2.46-3.95 (m, 24H), 2.41-2.44 (m, 4H), 1.83 (m, 2H).
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C NMR (125 MHz, D2O): δ = 21.7, 34.7, 42.5, 42.7, 47.4, 52.5, 55.9, 57.2, 58.8, 60.1, 116.2

(TFA), 127.7, 128.0, 128.5, 130.3, 135.4, 138.5, 143.5, 157.3, 162.9 (TFA), 166.3, 175.7, 175.8.
ESI-MS(+): m/z = 717.6 [M+H]+. HRMS (ESI): m/z calcd. for C36H57N14O2: 717.4789; found:
717.4788.

3.4.5 Synthesis of Tz-PEG7-AF680
Tz-PEG7-AF780 was synthesized according to previously published protocols.51 To
summarize, Tz-PEG7-NH2 (0.3 mg; 0.46 mol; 651.8 g/mol) was dissolved in 500 μL DMSO
and added to 0.5 mg AF680-NHS (0.46 mol; 1.0 equiv.; ~1150 g/mol). 0.8 μL triethylamine
(0.5 mg; 5.5 mol; 101.2 g/mol) was then added to this solution, and the solution was placed on
an agitating thermomixer at 300 rpm for 3 hours at room temperature. After 3 hours, the reaction
was purified via preparative C18 HPLC using a gradient of 5:95 CH3CN:H2O (both with 0.1%
TFA) to 95:5 CH3CN:H2O over 30 min (tR = 14.2 min). Lyophilization of the HPLC eluent
yielded the purified product as 0.28 mg of a deep blue powder (MW ~1750; ~0.16 mol; ~56.0%
yield).

38

3.4.6 Preparation of [64Cu]Cu-SarAr-Tz
[64Cu]Cu-SarAr-Tz was radiolabeled according to previously published protocols51. To
summarize, a solution of Tz-SarAr (5-25 µg; 6.9-34.9 nmol) in NH4OAc buffer (0.2 M, pH 5.5,
200 µL) was first prepared. Then, the desired amount of 64CuCl2 in 0.1 M HCl (1500-7500 µCi)
was added to the reaction mixture, and the solution was placed on an agitating thermomixer at
300 rpm for 30 minutes at room temperature. After this incubation, the

64

Cu-Tz-PEG7-NOTA

was purified via reverse phase C18 HPLC (tR = 8.7 min) to yield the completed radioligand in
>99% radionuclidic purity, and a specific activity of 730 ± 56 µCi/µg (523 ± 40 mCi/µmol) (n =
4).

3.4.7 Determination of the TCO occupancy of huA33-TCO, huA33-PEG12-TCO, and sshuA33PEG12-TCO
A solution of immunoconjugate — huA33-TCO, huA33-PEG12-TCO, or sshuA33-PEG12TCO) (50 µg; 0.33 nmol) — in 480 µL PBS (pH 7.4) was first prepared. To this solution, 20 µL
of a 0.42 mM solution of Tz-PEG7-AF680 in DMSO was added to create a reaction solution of
500 µL and concentrations of 0.66 µM immunoconjugate and 16.8 µM Tz-PEG7-AF680 (a ~25
fold excess of Tz). This solution was placed on an agitating thermomixer at 300 rpm for 180
minutes

at

room

temperature.

After

incubation,

the

resulting

fluorophore-labeled

immunoconjugate was purified using size-exclusion chromatography (Sephadex G-25 M, PD-10
column, GE Healthcare; dead volume = 2.5 mL, eluted with 2 mL fractions of PBS, pH 7.4) and
concentrated with centrifugal filtration units with a 50,000 molecular weight cut off (AmiconTM
Ultra 2mL, Millipore Corp., Billerica, MA) and PBS (pH 7.4). The degree of labeling (DOL)
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was determined via UV-Vis. Absorbance measurements were taken at 280 nm and 680 nm in
triplicate for each batch of immunoconjugate. The DOL was calculated using the following
formulas:
AmAb = A280 – Amax(CF)
DOL = [Amax*MWmAb]/[[mAb]*AF680]
where the correction factor (CF) for AF680 was given as 0.05 by the supplier, MW huA33 =
150,000, 680,AF680 = 184,000, and 280, mAb = 225,000. The degree of labeling of AF680 was taken
as the degree of labeling of TCO due to the rapid and quantitative nature of the IEDDA reaction.

3.4.8 MALDI-ToF Mass Spectrometry
As an additional verification and quantification of the number of PEG12-TCO ligands per
antibody, the immunoconjugates were analyzed by MALDI-ToF MS/MS using a Bruker
Ultraflex MALDI-ToF/ToF (Bruker Daltonic GmbH). 1 μL of each sample (1 mg/mL) was
mixed with 1 μL of sinapic acid (10 mg/ml in 50% acetonitrile:water and 0.1% trifluoroacetic
acid). 1 μL of the sample/matrix solution was spotted onto a stainless steel target plate and
allowed to air dry. All mass spectra were obtained using a Bruker Ultraflex MALDI-ToF/ToF
(Bruker Daltonic GmbH). Ions were analyzed in positive mode and external calibration was
performed by use of a standard protein mixture (Bovine Serum Albumin).
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3.4.9 Immunoreactivity Assays
Immunoreactivity assays employing the sshuA33-PEG12-TCO immunoconjugate labeled
with the [64Cu]Cu-SarAr-Tz were performed in quintuplicate as previously reported using A33
antigen-expressing SW1222 human colorectal cancer cells.73, 74

3.4.10 SDS-PAGE Analysis of the Antibody Conjugation
1 µg antibody (2 µL of a 0.5 mg/mL stock) was combined with 18.5 µL H 2O, 3 µL 500
mM dithiothreitol (NuPAGE® 10X Sample Reducing Agent, Life Technologies), and 7.5 µL 4X
electrophoresis buffer (NuPAGE® LDS Sample Buffer, Thermo Fisher, Eugene, OR). This
mixture was then denatured by heating to 85 °C for 15 min using an agitating thermomixer.
Subsequently, 20 µL of each sample was then loaded alongside an appropriate molecular weight
marker (Novex® Sharp Pre-Stained Protein Ladder, Life Technologies) onto a 1 mm, 10 well 412% Bis-Tris protein gel (Life Technologies) and run for ~3 h at 110 V in MOPS buffer. The
completed gel was washed 3 times with H2O, stained using SimplyBlueTM SafeStain (Life
Technologies) for 1 h, then destained overnight in H2O. The gel was then analyzed using an
Odyssey CLx Imaging system (Li-Cor Biosciences, Lincoln, NE).

3.4.11 PNGaseF Treatment of Antibody
HuA33, sshuA33-N3, and sshuA33-PEG12-TCO(10 µg) in each 10 µL PBS were denatured
by being mixed with 1 μL 10X DTT (New England Biolabs, Ipswich, MA) and heated at 55 °C
for 10 minutes. Subsequently, 18 µl H2O, 2 µL 500 mM sodium phosphate, pH 7.5 (G7 reaction
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buffer from New England BioLabs). Finally, 1 µl PNGase F was introduced to the sample (New
England BioLabs) and incubated overnight at 37 °C. After incubation, SDS-PAGE
electrophoresis was employed to analyze the PNGaseF-treated samples alongside samples
denatured and prepared as described above in “SDS-PAGE Analysis of the Antibody
Conjugation”.

3.4.12 Cell Culture
Human colorectal cell line SW1222 was obtained from the Ludwig Institute of Cancer
Research and maintained in Minimum Essential Medium, supplemented with 10% heatinactivated fetal calf serum, 2 mM glutamine, 100 units/mL penicillin, and 100 units/mL
streptomycin in a 37°C environment containing 5% CO2. Cell lines were harvested and passaged
every 8-10 days using 0.25% trypsin/0.53 mM EDTA in Hank’s Buffered Salt Solution without
calcium and magnesium.

3.4.13 Xenograft Models
All animal experiments were performed under an Institutional Animal Care and Use
Committee-approved protocol, and the experiments followed institutional guidelines for the
proper and humane use of animals in research. Six to eight week-old female athymic nude mice
were obtained from Harlan Laboratories (Indianapolis, IN). Animals were housed in ventilated
cages, given food and water as needed, and allowed to acclimatize for approximately 1 week
prior to inoculation. SW1222 tumors were implanted on the right shoulder by a subcutaneous
injection of 5.0 x 106 cells in a 200 μL cell suspension of a 1:1 mixture of fresh media:BD
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Matrigel (BD Biosciences, Bedford, Ma). The xenografts reached the ideal size for imaging and
biodistribution (~100-150 mm3) in approximately 2-3 weeks.

3.4.14 Pretargeted PET Imaging Experiments
All pretargeted PET imaging experiments were performed on an Inveon PET/CT scanner
(Siemens Healthcare Global). Female athymic nude mice (n = 5) bearing subcutaneous SW1222
(right shoulder) xenografts (100-150 mm3, 14-17 days post-inoculation) were administered 100
g (0.66 nmol) sshuA33-PEG12-TCO (in 200 L sterile PBS) via intravenous tail vein injection.
After an accumulation interval of 24 or 48 h, the same mice were then administered [64Cu]CuSarAr-Tz (300-350 Ci in 200 L sterile PBS), also via intravenous tail vein injection (t = 0).
The specific activity of the radiotracer was adjusted using cold Cu-Tz-SarAr such that the molar
ratio of Tzinjected:huA33injected  1:1. Approximately 5 minutes prior to the PET images, mice were
anesthetized by inhalation of 2% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen gas
mixture and placed on the scanner bed whereupon anesthesia was maintained using 1%
isoflurane/gas mixture. Static scans were recorded at various time points after injection with a
minimum of 30 million coincident events (10-30 min total scan time). An energy window of
350-700 keV and a coincidence timing window of 6 ns were used. Data were sorted into 2dimensional histograms by Fourier re-binning, and the images were reconstructed using a twodimensional ordered subset expectation maximization (2DOSEM) algorithm (16 subsets, 4
iterations) into a 128 × 128 × 159 (0.78 × 0.78 × 0.80 mm) matrix. The image data was
normalized to correct for non-uniformity of response of the PET, dead-time count losses,
positron branching ratio, and physical decay to the time of injection though no attenuation,
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scatter, or partial-volume averaging correction was applied. Activity concentrations (percentage
of dose per gram of tissue [%ID/g]) and maximum intensity projections were determined by
conversion of the counting rates from the reconstructed images. All of the generated PET images
were analyzed using ASIPro VM™ software. Whole-body CT scans were acquired with a
voltage of 80 kV and 500 μA. 120 rotational steps for a total of 220° were acquired with a total
scan time of 120 s and 145 ms per frame exposure. Combined PET/CT images were processed
using Inveon Research Workplace software (Siemens Healthcare Global).

3.4.15 Pretargeted Biodistribution Experiments
Female athymic nude mice bearing subcutaneous SW1222 (right shoulder) xenografts
(100-150 mm3, 14-17 days post-inoculation) were administered 100 g (0.66 nmol) of either
huA33-TCO, huA33-PEG12-TCO, or

huA33-PEG12-TCO (in 200 L sterile PBS) via

ss

intravenous tail vein injection. After an accumulation interval period of 24 or 48 h the same mice
were then administered [64Cu]Cu-SarAr-Tz (500 Ci in 200 L sterile PBS), also via intravenous
tail vein injection (t = 0). The specific activity of the radiotracer was adjusted using cold Cu-TzSarAr such that the molar ratio of Tzinjected:huA33injected = 1:1. Animals (n = 4 per group) were
euthanized by CO2(g) asphyxiation followed by cervical dislocation at 1, 4, 12, and 24 h after
injection. Following euthanasia, tissues were removed, rinsed in water, dried in air for 5 min,
weighed, and counted in a gamma counter calibrated for

64

Cu. Counts were converted into

activity using a calibration curve generated from known standards. Count data were backgroundand decay-corrected to the time of injection. The percent injected dose per gram (%ID/g) for
each tissue sample was calculated by normalization to the total activity injected.
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3.4.16 Ex Vivo Autoradiography, Immunohistochemistry, and Histology
Following PET imaging, tumors were excised and embedded in optimal-cuttingtemperature mounting medium (OCT, Sakura Finetek) and frozen on dry ice. Series of 10 μm
frozen sections were then cut. To determine radiotracer distribution, digital autoradiography was
performed by placing tissue sections in a film cassette against a phosphor imaging plate (Fujifilm
BAS-MS2325; Fuji Photo Film) for an appropriate exposure period at −20°C. Phosphor imaging
plates were read at a pixel resolution of 25 μm with a Typhoon 7000 IP plate reader (GE
Healthcare). Following autoradiographic exposure, the same frozen sections were then used for
fluorescence staining and microscopy. Immunofluorescence staining and imaging of the A33
antigen was performed as previously described.75 Frozen sections were fixed in 4%
paraformaldehyde, and subsequently incubated with huA33 primary antibody (5 μg/ml)
overnight at 4 C, followed by secondary detection using goat anti-human AlexaFluorTM-568 for
1 h at room temperature (20 μg/ml, Molecular Probes). Whole mount fluorescence images were
acquired at 40× magnification using a BX60 fluorescence microscope (Olympus America, Inc.)
equipped with a motorized stage (Prior Scientific Instruments Ltd.) and CC12 camera
(Olympus). Whole-tumor montage images were obtained by acquiring multiple fields at 40×
magnification, followed by alignment using MicroSuite Biologic Suite (version 2.7; Olympus).
Fluorescence and autoradiographic images were co-registered using Adobe Photoshop (CS6) as
previously described.76
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3.4.17 Dosimetry
Mouse biodistribution data were expressed as normal-organ mean standard uptake values
(SUVs) versus time post-administration. Assuming, in first order, that SUVs are independent of
body mass and thus the same among species, the mean SUV in mouse organ i, SUVOrgan i|Mouse,
was converted to the fraction of the injected dose in each human organ I, FID Organ I|Human, using
the following formula:

FIDOrgan i|Human =

Mass of Human Organ i
SUVran i|Mouse  Mass of Human Total Body

and the organ and total-body masses of the 70-kg Standard Man anatomic model.77 These data
(corrected for radioactive decay to the time of injection) were then fit to a mono-exponential or
bi-exponential time-activity function, depending on the organ. The cumulated activity — or
residence time — in each organ (in Ci-h/Ci) was then calculated by analytically integrating
the time-activity function in the organ, replacing the biological clearance constant with the
corresponding effective clearance constant corrected for the physical decay constant of the
radionuclide. The resulting organ residence times were entered into the OLINDA computer
program to yield the mean organ absorbed doses and effective dose in rad/mCi and rem/mCi,
respectively.78
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Chapter 4: Dendrimer Scaffold Leads to Amplification of In Vivo
Ligation
Disclaimer: The following text was adapted from material in review:
Cook, B. E.; Membreno, R.; Zeglis, B. M., A Dendrimer Scaffold for the Amplification
of In Vivo Pretargeting Ligations. Bioconjugate Chemistry 2018. (in review) American Chemical
Society.

4.1 Introduction
Over the past three decades, the ability of antibodies to selectivity and specifically deliver
cargoes such as toxins, fluorophores, or radionuclides to sites of disease has fueled the advent of
immunoconjugates in both the laboratory and the clinic. The construction of an
immunoconjugate often requires a delicate balancing act between functionalizing the antibody
with enough cargo molecules to facilitate the in vivo purpose of the final construct but not so
many that the immunoreactivity or pharmacokinetic profile of the antibody suffer. In this sense,
for a given antibody, each bioconjugation reaction is a double-edged sword that simultaneously
offers the reward of a more potent immunoconjugate but also the risk of a biochemically
diminished vector. This is particularly true of immunoconjugates for in vivo pretargeting.
In vivo pretargeting is an approach to nuclear imaging and therapy that seeks to harness the
tumor targeting properties of antibodies while skirting their pharmacokinetic limitations. To this
end, in vivo pretargeting is predicated on decoupling the antibody and the radionuclide, injecting
separately, and allowing them to combine within the body. We have previously developed an
effective strategy for in vivo pretargeted imaging and therapy based on the rapid and
bioorthogonal inverse electron demand Diels-Alder (IEDDA) ligation between a trans-
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cyclooctene-modified antibody (mAb-TCO) and a tetrazine (Tz)-bearing radioligand. In
pretargeted PET, the mAb-TCO construct is administered first and allowed time  typically one
to five days  to accumulate at the tumor site and clear from the blood. Subsequently, the
radiolabeled tetrazine is injected, whereupon it either clicks with the TCO-bearing
immunoconjugate at the tumor or rapidly clears from the body (Figure 1.1). In this way, in vivo
pretargeting enables the use of radionuclides that are normally incompatible with antibody-based
vectors (e.g.

18

F,

68

Ga, and

64

Cu), thereby accelerating workflows and dramatically reducing

radiation doses to healthy organs compared to traditional immunoPET.
We have recently used a chemoenzymatic bioconjugation strategy developed in our
laboratory to create a site-specifically modified mAb-TCO immunoconjugate in which TCO
moieties are attached to the heavy chain glycans. While this construct proved effective for
pretargeted PET, the modification method only allowed for the attachment of 2 TCOs per
antibody due to steric hindrance within the Fc domain. It stands to reason that increasing the
number TCOs on each antibody could increase the efficiency of the in vivo ligation  and thus
uptake in the tumor  by providing more “click partners” for the Tz-bearing radioligand.
Furthermore, it has been reported that TCOs can isomerize (albeit slowly) to inactive ciscyclooctenes in vivo, effectively reducing the number of reactive sites for the radioligand.79, 80 In
light of this, increasing the number of TCOs per antibody could improve the odds of reactive
isomers remaining intact following longer pretargeting intervals. This line of thought returns us
to the balancing act that we discussed earlier: how we can maximize the number of TCOs while
simultaneously limiting the number of bioconjugation sites? During a careful reading of the
literature, one solution in particular jumped out: disulfide-core PAMAM dendrimers.
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Disulfide-core PAMAM dendrimers have previously been explored as platforms for the
conjugation of large number of drugs, radionuclides, and contrast agents to antibodies.81-83 While
the loading capacity of these constructs is impressive, most  if not all  dendrimer-bearing
immunoconjugates have been plagued by poor in vivo behavior, producing higher uptake in the
liver and spleen and lower accumulation in the tumor than traditional immunoconjugates.81, 84, 85
It is likely that these constructs underperformed because the dendrimers interfered with the
ability of the antibodies to specifically and selectively bind to their molecular targets. 81,

86

However, this work nonetheless provides an exciting glimpse into the potential of this approach
should these limitations be overcome.
Herein, we report the development of a novel TCO-bearing ligand based on a disulfide-core
PAMAM dendrimer as well as the use of this construct to improve the performance of
pretargeted PET imaging. The branching nature of the ligand reminds the authors of Yggdrasil,
the world-encompassing tree of Norse mythology. As such, the dendrimer-bearing
immunoconjugates described in this work will be referred to as ‘yggdratic antibodies’.

4.2 Results and Discussion
4.2.1 Design
Any IEDDA-based pretargeting system is composed of two essential elements: a TCObearing immunoconjugate and a Tz-based radioligand. In this investigation, we chose to employ
the huA33 antibody and the [64Cu]Cu-SarAr-Tz radioligand. The former is a humanized IgG1
that targets the A33 antigen, a transmembrane glycoprotein expressed by >95% of colorectal
carcinomas.28 The latter has been has previously been demonstrated to exhibit rapid renal
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excretion as well as a favorable pharmacokinetic profile.87 Critically, upon binding its target,
huA33 remains persistent on the outside of cells, thereby facilitating the click reaction between
its putative TCO cargo and a Tz-bearing radioligand.
The final piece of the puzzle  the TCO-bearing dendrimer  will be discussed shortly.
However, one last design consideration should be addressed: bioconjugation. In order to reduce
the chances of the TCO-bearing dendrimer interfering with the antibody’s ability to bind its
target, we have decided to employ a chemoenzymatic approach to bioconjugation developed in
our laboratory.59 In this approach, the antibody is first treated with EndoS, an endoglycosidase
that hydrolyzes the chitobiose core of the asparagine-linked heavy chain glycans. Subsequently,
the immunoconjugate is treated with a promiscuous galactosyltransferase  Gal-T(Y289L) 
and an azide-modified monosaccharide  GalNAz  in order to incorporate azides into the
residual glycan chains. The azide-bearing antibody can then be modified easily using
dibenzocyclooctyne-bearing substrates via the strain-promoted azide-alkyne click ligation
(SPAAC).

4.2.2 Construction of the TCO-Bearing Dendrimer
Disulfide-core PAMAM dendrimers provide a versatile, commercially-available, and
hydrophilic scaffold. They can be modified on the NH2-bearing 'branches' using amine-reactive
reagents and  after reduction  on the sulhydryl-containing ‘trunk’ with thiol-reactive
moieties. In this case, we set out to modify the former with TCOs and the latter with a PEG 5containing variant of DBCO for SPAAC. The synthesis of the TCO-bearing dendrimer was
performed in three steps with a global yield of 33.2% (Figure 4.1). The G1 starting material was
first reduced using TCEP for 1 h at 25 °C. Without purification, DBCO-PEG5-maleimide was
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added in molar excess, and the reaction mixture was incubated at 25 °C for 24 h to produce G0.5PAMAM-PEG4-DBCO or, more simply, Ygg-DBCO. Following chromatographic purification,
Ygg-DBCO was incubated under basic conditions with a vast molar excess of TCO-NHS at 25
°C for 48 h. The final product  DBCO-Ygg-TCO4  was purified via reversed phase C18
HPLC. Characterization by high resolution mass spectrometry revealed that the maleimide
linkage underwent hydrolysis; however it has been demonstrated in literature that this affects
neither the linkage nor the utility of the molecule.88

Figure 4.1 Synthesis of Yggdratic Ligand.

4.2.3 Bioconjugation
As we noted above, a chemoenzymatic strategy was used to site-specifically attach the YggTCO ligands to huA33 (Figure 4.2). To this end, huA33 was first treated with EndoS and then
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GalT(Y289L)/GalNAz in order to incorporate azides into the heavy chain glycans of the
antibody, ultimately producing sshuA33-N3. DBCO-Ygg-TCO was then conjugated to sshuA33N3 via overnight incubation in aqueous buffer at 25°C. The final product  sshuA33-Ygg-TCO
 was purified via size exclusion chromatography and characterized by MALDI-ToF which
confirmed the presence of 1.7-2.0 Ygg-TCO/mAb. This, of course, means that each sshuA33Ygg-TCO construct boasts 6.8-8.0 TCO/mAb. The specificity of the bioconjugation was
validated via PAGE, which clearly displayed a positive shift in the mass of the heavy chain but
no shift in the mass of the light chain. As a control construct, sshuA33-Ygg-NH2 was synthesized
in a similar manner using DBCO-Ygg-NH2. In this case, MALDI-ToF likewise confirmed a
degree of labeling of ~2 Ygg-NH2/mAb.
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Figure 4.2: Schematic of two different methods to site-specifically modify the heavy chain
glycans of an antibody. 1) Cleavage of the heavy chain by either EndoS or β-1,4-galactosidase,
2) addition of an azide residue via GalT, 3) attachment of DBCO-ligands by SPAAC with azide.

The site-specifically labeled, TCO-bearing huA33 immunoconjugate that we have previously
published, sshuA33-PEG12-TCO, was chosen as a ‘dendrimer-lacking’ control immunoconjugate
for the investigation. The synthesis of this construct  which differs slightly from that of
huA33-Ygg-TCO  has been published.89

ss

Briefly, huA33 was first treated with -1,4-

galactosidase and then GalT(Y289L)/GalNAz in order to incorporate azides into the heavy chain
glycans of the antibody (Figure 4.2). Unlike EndoS, -1,4-galactosidase cleaves only the final
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galactose residues of the biantennary glycans, meaning this method facilitates the incorporation
of a total of four azides into the glycans. The ligand DBCO-PEG12-TCO was then conjugated to
the azide-modified antibody, creating the finished product: sshuA33-PEG12-TCO. Despite the
presence of four azides, MALDI-ToF analysis revealed that sshuA33-PEG12-TCO had a degree of
labeling of only ~2 TCO/mAb, likely due to steric hindrance within the Fc region of the
antibody.
The immunoreactivity of both

ss

huA33-Ygg-TCO and

ss

huA33-PEG12-TCO were tested

prior to in vivo studies via antigen saturation binding assays using SW1222 cells expressing the
A33 antigen. In early assays, sshuA33-Ygg-TCO displayed a high degree of non-specific binding
to the microcentrifuge tubes, though this was soon circumvented via the use of tubes pretreated
with BSA. Ultimately, the immunoreactive fractions of sshuA33-Ygg-TCO and sshuA33-PEG12TCO were found to be 0.88 ± 0.025 and 0.97 ± 0.01, respectively.

4.2.4 Pretargeted PET Imaging and Biodistribution
PET imaging and biodistribution experiments were performed to explore the efficacy of in
vivo pretargeting with sshuA33-Ygg-TCO and [64Cu]Cu-SarAr-Tz. To this end, athymic nude
mice bearing subcutaneous SW1222 human colorectal cancer xenografts were first injected with
either sshuA33-Ygg-TCO or sshuA33-PEG12-TCO (100 μg, 0.67 nmol), followed 120 h later with
the administration of [64Cu]Cu-SarAr-Tz (16.7 MBq; 450 μCi, 1.75 nmol). It is important to note
that we used a particularly long lag time (120 h) in this investigation in order to probe if this new
technology could improve the performance of these pretargeting systems following long
pretargeting intervals. Static PET scans were performed 4 and 24 h after the injection of the
radioligand (Figure 4.3A). Immediately after the second set of PET scans, the two cohorts of
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mice were sacrificed, and their organs were harvested, washed, dried, weighted, and assayed for
radioactivity on an automated gamma counter (Figure 4.3B).

Figure 4.3: Preinjection study of athymic nude mice (n = 3) bearing subcutaneous SW1222
xenografts on their right shoulder receiving 100 μg (0.67 nmol) of either sshuA33-TCO or
ss
huA33-Ygg-TCO followed 120 h later by an injection of [64Cu]Cu-SarAr-Tz (16.7 MBq, 0.75
nmol). (A) PET imaging at 4 h (top) and 24 h (bottom) post-injection of radioligand showing
clear tumor delineation. Inserts are of maximal intensity projections for each time point. (B)
Biodistribution at 24 h post injection of radioligand demonstrating significantly higher tumor
uptake in mice treated with sshuA33-Ygg-TCO.

The differences between the in vivo performance of the two systems are readily apparent in
both the images and the biodistribution. Most notably, sshuA33-Ygg-TCO produces double the
tumoral activity concentration of sshuA33-PEG12-TCO: 8.9 ± 1.9 %ID/g vs. 4.1 ± 1.3 %ID/g,
respectively.

Background uptake is observed in the kidneys for both groups and can be

attributed to retention of the radioligand, [64Cu]Cu-SarAr-Tz.87

At the same time, blood and

blood-perfused organs (heart, lung, liver) demonstrate noticeably higher uptake in mice
administered yggdratic antibody. The higher blood value in particular (2.0 ± 1.0% ID/g for
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ss

huA33-Ygg-TCO compared with 0.8 ± 0.4% ID/g for

ss

huA33-PEG12-TCO) prompted an

investigation into the blood half-life of the two constructs (discussed below).

Figure 4.4: Low-dose preinjection study in athymic nude mice (n = 5) bearing subcutaneous
SW1222 xenografts on their right shoulder receiving 13 μg (0.083 nmol) of either sshuA33-TCO
or sshuA33-Ygg-TCO followed 120 h later by an injection of [64Cu]Cu-SarAr-Tz (16.7 MBq,
0.75 nmol). (A) PET imaging at 4 h (top) and 24 h (bottom) post-injection of radioligand
showing clear tumor delineation. Inserts are of maximal intensity projections for each time
point. (B) Biodistribution at 24 h post injection of radioligand with overlay of 100 μg
preinjection of sshuA33-TCO from Figure 4.3.

These promising data prompted a second experiment using much lower doses of
immunoconjugates. In this case, athymic nude mice bearing SW1222 xenografts were
administered 8-fold lower doses of either sshuA33-Ygg-TCO or sshuA33-PEG12-TCO (13 μg,
0.083 nmol), followed 120 h later with [64Cu]Cu-SarAr-Tz (16.7 MBq; 450 μCi, 1.75 nmol).
Again, static PET scans were collected at 4 and 24 h, and the 24 h scan was followed with a
biodistribution study (Figure 4.4). The major trends observed in the initial experiment were
evident here as well. sshuA33-Ygg-TCO produced higher activity concentrations in the tumor
(4.8 ± 0.9 %ID/g) than sshuA33-PEG12-TCO (2.3 ± 0.7 %ID/g). Furthermore, the yggdratic
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antibody yielded a significantly higher tumor-to-blood activity concentration ratio than its
dendrimer-lacking cousin: 7.4 ± 1.8% ID/g vs. 4.5 ± 1.4% ID/g(P<0.005). In fact, tumor-tobackground ratios between most sampled organs were higher (P<0.05) for sshuA33-Ygg-TCO,
including kidney, muscle, small intestine, large intestine, liver, and spleen (Figure 4.7). Notably,
it can be seen that pretargeting with 13 μg (0.083 nmol) of sshuA33-Ygg-TCO produces similar
results to pretargeting with 8 times more sshuA33-PEG12-TCO. Clearly, the availability of ~8
TCOs/mAb on sshuA33-Ygg-TCO compared to ~2 TCOs/mAb on sshuA33-PEG12-TCO not only
boost the activity concentrations in the tumor at higher doses of immunoconjugate but also
enables effective pretargeted PET with much lower doses of the immunoconjugate.

4.2.5 Blood Serum Clearance Pharmacokinetics
In the pretargeting experiments that employed 100 μg of the immunoconjugates, sshuA33Ygg-TCO (2.0 ± 1.0 %ID/g) produced much higher activity concentrations in the blood than
ss

huA33-PEG12-TCO (0.8 ± 0.4 %ID/g). These data suggested the

ss

huA33-Ygg-TCO

immunoconjugate has a longer pharmacokinetic half-life in serum than sshuA33-PEG12-TCO.
This is, perhaps, not surprising in light of the large dendrimeric scaffolds attached to the former.
However, a more thorough investigation was certainly warranted. So, in an effort to explore the
clearance of these immunoconjugates from the blood more quantitatively, a serum half-life study
was performed. Each immunoconjugate was modified non-site-specifically with the bifunctional
chelator DFO-NCS in order to facilitate radiolabeling with positron-emitting radiometal 89Zr. We
selected 89Zr-based imaging as means to track the constructs in vivo for two reasons: (1) the long
half-life of 89Zr (t1/2 ~ 3.3 d) allowed us to follow the immunoconjugates over several days and
(2) we wanted the TCO moieties of the immunoconjugates to remain intact throughout the
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experiment, a desire which eliminates the possibility of using a Tz-based radioligand to label the
constructs. In addition to the two constructs that we have discussed, three other huA33-based
immunoconjugates were modified with DFO and studied as controls: native huA33, huA33 that
had been deglycosylated with EndoS, and sshuA33-Ygg-NH2. Healthy female athymic nude mice
(n = 5) were administered 2.2 MBq of each

89

Zr-DFO-labeled radioimmunoconjugate.

Subsequently tail-vein blood draws were then carried out at 2, 6, 24, 48, 72, 120, and 144 h postinjection, and the blood from each sampling was weighed and assayed for radioactivity on a counter. PET images were also obtained to visualize the in vivo behavior of each construct
(Figure 4.5).
The serum half-life of sshuA33-Ygg-TCO (t1/2 ~ 78 h) was dramatically longer than that of
ss

huA33-PEG12-TCO (t1/2 ~ 30 h), with significantly higher activity in the blood at 144 h post-

injection of antibody (P < 0.0005). Interestingly, the half-life of sshuA33-PEG12-TCO was most
similar to that of native huA33, while the half-life of sshuA33-Ygg-TCO was far closer to that of
the EndoS-deglycosylated antibody (Figure 4.9). This suggests that in this case, the
glycosylation state of the antibody has a stronger influence on the blood clearance of the
antibody than the presence of the dendrimer scaffold. Furthermore, sshuA33-Ygg-NH2 exhibited
a similar rate of clearance to

ss

huA33-Ygg-TCO despite differences in the charge and

lipophilicity of the dendrimers attached to each construct dendrimers. This result opens the
possibility that dendrimeric ligands bearing a wide variety of cargoes could be attached to
antibodies without dramatically changing their clearance profiles, though of course more study in
this area is needed.
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Figure 4.5: Blood clearance curves for various huA33 immunoconjugates. Insert shows final
blood values at 144 h in % ID/g (*P<0.005).

4.3 Conclusion
In the preceding pages, we have described the synthesis, characterization, and in vivo
application of a bifunctional, TCO-bearing dendrimeric ligand: Ygg-TCO. A site-specifically
modified immunoconjugate decorated with a pair of these yggdratic ligands — sshuA33-YggTCO — proved to be a highly effective platform for pretargeted PET imaging. Indeed,
pretargeted PET and biodistribution experiments in a murine model of colorectal carcinoma
revealed that

ss

huA33-Ygg-TCO produced dramatically improved absolute tumoral activity

concentrations and tumor-to-background activity concentration ratios compared to an analogous,
dendrimer-lacking immunoconjugate (of sshuA33-PEG12-TCO). Just as notably, the yggdratic
immunoconjugate facilitated effective in vivo pretargeting at 1/8th the dose of antibody normally
employed for such experiments. The foundation of this improved performance almost certainly
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lies in the higher number of TCOs/mAb on sshuA33-Ygg-TCO, a trait that not only provides
more in vivo reaction partners for tetrazine radioligands but also acts as ‘insurance’ against the
slow isomerization of trans-cyclooctene to cis-cyclooctene in the body. Moving beyond
pretargeting, we also believe that this work could have more general implications for
bioconjugation chemistry. More specifically, we have demonstrated that our dendrimeric ligands
can be site-specifically attached to an antibody without significantly impairing its ability bind its
target in vivo. It is important to note, however, that while this bioconjugation strategy preserves
the integrity of the immunoglobulin, it also appears to increase the serum half-live of the
immunoconjugate. Ultimately, it is our hope that this study has an ongoing impact not only on
the study of in vivo pretargeting but also on the field of bioconjugation chemistry as a whole.

4.4 SUPPLEMENTAL: Materials and Methods
Unless otherwise noted, all chemicals were acquired from Sigma-Aldrich (St. Louis, MO)
and were used as received without further purification. All water employed was ultrapure (>18.2
MΩcm-1at 25 °C), all DMSO was of molecular biology grade (>99.9%), and all other solvents
were of highest grade commercially available. Amine-reactive trans-cyclooctene [(E)-cyclooct4-enyl 2,5-dioxo-1-pyrrolidinyl carbonate; TCO-NHS)] and amine-reactive tetrazine (2,6-dioxo1-pyrrolidinyl

5-[4-(1,2,4,5-tetrazin-3-yl)benzylamino]-5-oxopentanoate;

Tz-NHS)

were

purchased form Sigma-Aldrich (St. Louis, MO), p-NCS-Bn-DFO and DiAmSar chelators were
purchased from Macrocyclics (Dallas, TX), and [64Cu]Cu-SarAr-Tz and Tz-PEG7-AF680 were
synthesized as previously reported.87 Disufide dendrimer (code AuCS-294) was purchased from
Andrews ChemServices (Berrien Springs, MI). DBCO-PEG4-Maleimide was purchased from
Click Chemistry Tools (Scottsdale, AZ). Humanized A33 (huA33) was generously provided by
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the Ludwig Institute and stored at -80 °C prior to use. Remove-iTTM EndoS enzyme was
purchased from New England BioLabs (Ipswich, MA) and Gal-T(Y289L) purchased from
ThermoFisher (Waltham, MA).

64

Cu was purchased from Washington University, St. Louis,

where it was produced on a medical cyclotron (Model CS-15, Cyclotron Corporation) via the
64

Ni(p,n)64Cu transformation and purified as previously described to yield [64Cu]CuCl2 with an

effective specific activity of 518 ± 259 GBq/µmol (14,000 ± 7600 mCi/µmol).90,

91

Amine-

reactive AlexaFluor 680 (AF680-NHS) was purchased from ThermoFisher Scientific (Waltham,
MA). All experiments using laboratory animals were performed in accordance with protocols
approved by the Memorial Sloan Kettering Institutional Animal Care and Use Committee.

4.4.1 Synthesis of G0.5PAMAM-SH
Reduction of the G1-PAMAM cystamine-core dendrimer took place in an aqueous
reaction buffer (50 mM HEPES, 10 mM EDTA, 2.5 mM TCEP). 375 µL of dendrimer (105 mM
in ethanol) was added to 6 mL of buffer solution and let mix for 60 min at 25°C. Reaction
proceeded quantitatively as confirmed by analytical C18 HPLC using a gradient of 2:98
MeCN:H2O (both with 0.1% TFA) to 20:80 MeCN:H2O over 50 minutes (tR = 15.0 min).
HRMS (ESI) m/z: calcd for C68H109N17O15S, 1435.802; found, 1436.806. Reduced dendron
confirmed by HPLC and HRMS (ESI) m/z: calcd for C32H67N13O6S, 761.5058; found, 761.5124.

4.4.2 Synthesis of G0.5PAMAM-PEG4-DBCO “DBCO-Ygg-NH2”
Without purification, 3 molar equivalents of DBCO-PEG4-Maleimide (37.8 mg, 148 mM
in DMSO, 674.75 g/mol) were added and allowed to mix for 24 hours at 25 °C. The reaction
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was purified by preparative C18 HPLC using a gradient of 20:80 MeCN:H2O (both with 0.1%
TFA) to 80:20 MeCN:H2O over 20 minutes (tR = 13.5 min). Lyophilization of HPLC eluent
yielded the product as 22.97 mg of an orange, crystalline solid (MW = 1436.78 g/mol, 16.0
µmol, 40.6 %yield). HRMS (ESI) m/z: calcd for C68H109N17O15S, 1435.802; found, 1436.806.

4.4.3 Synthesis of (TCO)4-G0.5PAMAM-PEG4-DBCO “DBCO-Ygg-TCO”
G0.5PAMAM-PEG4-DBCO (6.5 mg, 4.5 µmol) was dissolved in DMSO to a final
concentration of 1.2 mM. Eighty molar equivalents of triethylamine (36.7 mg, 360 µmol, 101.2
g/mol) were added to this solution, followed by 20 molar equivalents of TCO-NHS (24.2 mg,
90.0 µmol, 267 g/mol). The solution was allowed to react at 25 °C over 48 h and purified by
preparative C18 HPLC using a gradient of 50:50 MeCN:H2O (both without TFA) to 100:0
MeCN:H2O over 30 minutes (tR = 23.5 min). HPLC eluent was lyophilized, yielding the product
as 7.59 mg of orange solid (MW = 2063.57, 3.68 µmol, 81.8 %yield). HRMS (ESI) m/z: calcd
for C104H159N17O24S, 2062.1465; found, 688.7231 [M + 3H]3+.

4.4.4 Synthesis of sshuA33-Ygg-TCO
Glycan Modification: HuA33 (10 mg, 11.92 mg/mL, in phosphate buffered saline [PBS],
pH 7.4) was buffer exchanged into antibody preparation buffer (50 mM Bis-Tris, 100 mM NaCl,
pH 6.0) using centrifugal filtration units with a 50,000 molecular weight cut-off (AmiconTM
Ultra, Millipore Corp., Billerca, MA). Following buffer exchange, an aliquot of the antibody (5
mg in 125 µL antibody preparation buffer) was combined with Remove-iTTM EndoS tagged with
a chitin-binding domain (35 µL, 200 U/µL) and 50 µL of the supplied G6 buffer (10x
62

concentrated) and diluted to 500 µL in water.

The mixture was placed on an agitating

thermomixer at 37 °C and 450 rpm overnight. The next day 175 µL of chitin magnetic bead
solution (New England BioLabs, Ipswich, MA) were washed with tris-buffered saline (TBS) and
mixed into the antibody-enzyme solution and placed on ice for 10 minutes. The chitin beads,
now binding the EndoS, were separated magnetically and the remaining deglycosylated huA33
solution was concentrated using centrifugal filtration units with a 50,000 molecular weight cutoff (AmiconTM Ultra, Millipore Corp., Billerca, MA).
GalNAz Modification: Deglycosylated huA33 (3.8 mg, 17.0 mg/mL in TBS) was then
combined with UDP-GalNAz (5 µL of a 40 mM solution), MnCl2 (2.5 µL of a 1 M solution),
Tris buffer (26 µL of a 1 M solution (pH 7.0)), Gal-T(Y289L) [15 µL of 0.29 mg/mL in 50 mM
Tris, 5 mM EDTA (pH 8.0)] and H2O (19 µL) and was incubated at 30 °C overnight. The
following day, GalNAz-modified antibodies were isolated using centrifugal filtration units with a
50,000 molecular weight cut-off (AmiconTM Ultra, Millipore Corp., Billerca, MA) and bufferexchanged into PBS (pH 7.4).
Yggdratic Ligand Ligation: sshuA33-Ygg-TCO: The purified GalNAz-modified antibody
was then combined with 120 µL (TCO)4-G0.5PAMAM-PEG4-DBCO (5 mM in DMSO) and
incubated at 25 °C overnight. The following day, the completed immunoconjugate, “sshuA33Ygg”, was purified via size exclusion chromatography (Sephadex G-25 M, PD-10 column, GE
Healthcare) and concentrated using centrifugal filtration units with a 50,000 molecular weight
cut-off (AmiconTM Ultra, Millipore Corp., Billerca, MA) with a final yield of 2.6 mg in 500 µL
PBS. MALDI-ToF spectra revealed a mass-difference between conjugated and un-conjugated
huA33 suggesting 1.7-2.0 yggdratic ligands-per-antibody.
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4.4.5 Synthesis of sshuA33-Ygg-NH2
800 µg of GalNAz-modified antibody was prepared as described, and combined with 27
µL DBCO-Ygg-NH2 (2 mM in DMSO) and incubated at 25 °C overnight. The following day,
the completed immunoconjugate, “sshuA33-PAMAM”, was purified via size exclusion
chromatography (Sephadex G-25 M, PD-10 column, GE Healthcare) and concentrated using
centrifugal filtration units with a 50,000 molecular weight cut-off (AmiconTM Ultra, Millipore
Corp., Billerca, MA) with a final yield of 2.6 mg in 500 µL PBS. MALDI-ToF spectra revealed
a mass-difference between conjugated and un-conjugated huA33 suggesting 1.7 ligands-perantibody.

4.4.6 Synthesis of sshuA33-PEG12-TCO (sshuA33-TCO)
Synthesis of

ss

huA33-PEG12-TCO was prepared as previously described.89

In brief,

huA33 antibody was modified by cleaving the terminal galactose residues from its heavy chain
glycans using β-1-4-galactosidase. These were then replaced as described above with an azidebearing galactose residue, GalNAz, by a promiscuous galactosyl transferase Gal-T(Y289L).
Finally, TCO-PEG12-DBCO was attached through SPAAC ligation to the GalNAz residue and
purified to yield the final product. MALDI-ToF confirmed the addition of 2 TCO ligands per
mAb.
4.4.7 Synthesis of DFO-Labeled huA33 Immunoconjugates
In order to study in vivo blood kinetics of the yggdratic antibody, a number of huA33
derivatives were radiolabeled with

89

Zr through the non-site-specific attachment of 1-(4-

isothiocyanatophenyl)-3-[6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetylhydroxylamino)64

6,11,17,22- tetraazaheptaeicosine] thiourea (p-SCN-Bn-DFO). The huA33 constructs modified
were as follows:

ss

huA33-Ygg-TCO,

ss

huA33-TCO, huA33, endoS-deglycosylated huA33

(endoS-huA33), and sshuA33-Ygg-NH2. A solution of 400 µg antibody in PBS (2.7 nmol, 2 g/L)
was adjusted to pH 8.7 using Na2CO3 (0.1 M). Next, five molar equivalents of P-SCN-Bn-DFO
(13.3 nmol, 2 mM in DMSO) were added and the reaction mixed for 1 hr at 37 °C. The
conjugates were then purified by size exclusion chromatography (Sephadex G-25 M, PD-10
column, GE Healthcare) and concentrated using centrifugal filtration units with a 50,000
molecular weight cut-off (AmiconTM Ultra, Millipore Corp., Billerca, MA) with yields between
77-95%.

4.4.8 Synthesis of Tz-SarAr
The ligand Tz-SarAr was synthesized as previously described.87

4.4.9 Radiolabeling of DFO-mAb constructs with 89Zr
89

Zr arrived as [89Zr]Zr-oxalate in 1 M oxalic acid and 3 mCi (111 MBq) was diluted to

100 µL in oxalic acid (1 M). The pH was adjusted to 7.4 with Na2CO3 (1 M) and the solution
then diluted to 500 µL in metal-free PBS (pH 7.4). 500 µCi aliquots were then mixed with
solutions containing 300 µg of huA33 constructs (DFO-sshuA33-Ygg, DFO-sshuA33-TCO,
DFO-huA33, DFO-endoS-huA33, DFO-sshuA33-PAMAM) to a total volume of 500 µL and let
mix at 25 °C for 1 h. Radiolabeling was verified as >98% RCY as determined by instant-thin
layer chromatography using glass microfiber chromatography paper impregnated with silica gel
(Varian Inc., Lake Forest, CA) as the stationary phase and 50 mM EDTA (pH 5.5) as the mobile
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phase. Finally, the radiolabeled constructs were purified by size exclusion chromatography
(Sephadex G-25 M, PD-10 column, GE Healthcare) in PBS (pH 7.4).

4.4.10 Radiolabeling of Tz-SarAr with 64Cu
Radiolabeling of Tz-SarAr with [64Cu]CuCl2 was carried out as previously described.87
In brief, an NH4OAc (0.1 M, pH 4.5) buffer solution containing Tz-SarAr (0.8 nmol) was mixed
with 185 MBq (5 mCi) 64CuCl2 at 25 °C for 20 minutes. RadioHPLC confirmed >99% yield, so
radioligand was used without further purification. The solution was diluted in 0.9% sterile saline
and pH adjusted with NaOH (5 M) to 7.4.

4.4.11 MALDI-ToF Mass Spectrometry
As a means by which to quantify the number of ligands per antibody, the
immunoconjugates were analyzed by MALDI-ToF MS/MS using a Bruker Ultraflex MALDIToF/ToF (Bruker Daltonic GmbH). 1 μL of each sample (1 mg/mL) was mixed with 1 μL of
sinapic acid (10 mg/ml in 50% acetonitrile:water and 0.1% trifluoroacetic acid). 1 μL of the
sample/matrix solution was spotted onto a stainless steel target plate and allowed to air dry. All
mass spectra were obtained using a Bruker Ultraflex MALDI-ToF/ToF (Bruker Daltonic
GmbH). Ions were analyzed in positive mode and external calibration was performed by use of a
standard protein mixture (Bovine Serum Albumin).
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4.4.12 SDS-PAGE Analysis of Antibody Conjugation
1 μg of antibody (2 μL of a 0.5 mg/mL stock) was combined with 18.5 μL H2O, 3 μL
500 mM dithiothreitol (NuPAGE® 10X Sample Reducing Agent, Life Technologies), and 7.5
μL 4X electrophoresis buffer (NuPAGE® LDS Sample Buffer, Thermo Fisher, Eugene, OR).
This mixture was then denatured by heating to 85 °C for 15 min using an agitating thermomixer.
Subsequently, 20 μL of each sample was loaded alongside an appropriate molecular weight
marker (Novex® Sharp Pre- Stained Protein Ladder, Life Technologies) onto a 1 mm, 10 well 412% Bis-Tris protein gel (Life Technologies) and run for ~3 h at 50 V in MOPS buffer. The gel
was washed 3 times with H2O, stained using SimplyBlueTM SafeStain (Life Technologies) for 1
h, and destained overnight in H2O. The gel was then analyzed using an Odyssey CLx Imaging
system (LI-COR Biosciences, Lincoln, NE)(Figure 4.6).

Figure 4.6: SDS-PAGE of yggdratic antibody synthesis. Red lines denote heavy (top) and light
(bottom) chains of the immunoconjugates.
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4.4.13 Saturation Binding Assay
Immunoreactivity of

ss

huA33-Ygg-TCO and

ss

huA33-PEG12-TCO conjugates was

determined using a saturation binding assay with SW1222 cells expressing the GPA33 antigen.
Briefly, 9 x 106 cells in 100 µL of PBS were aliquoted into Protein LoBind Eppendorf Tubes
(Eppendorf AG, Hanburg, Germany) that had been pre-treated 24 h in PBS+1% fetal bovine
serum. Concurrently, 150 µg of each mAb-TCO conjugate was separately mixed with [64Cu]CuSarAr-Tz in PBS (pH 7.4) for 1 h at 25 °C, then purified by size exclusion chromatography
(Sephadex G-25 M, PD-10 column, GE Healthcare) in PBS (pH 7.4). The resulting solution of
“pre-clicked” 64Cu-SarAr-mAb was diluted to 0.4 µg/mL and 2 ng aliquots were mixed with the
tubes of SW1222 cells. The tubes were placed on ice for 1 h after which they were pelleted by
centrifugation (4 min at 300 x g). The supernatant was then removed and set aside for counting.
PBS with 1% FBS was added to the tubes, which were then re-pelleted. Supernatant was again
removed and a second wash was performed. After washing, the activity in each of the tubes cell pellet, supernatant, wash 1, and wash 2 - was counted separately and the immunoreactive
fraction (taken here as percent bound) was calculated by dividing the counts in the cell pellet
with the sum counts in the supernatant and washes. Data were obtained in quintuplicate for each
construct.

4.4.14 Cell Culture
SW1222 human colorectal cancer cells, obtained from the Ludwig Institute of Cancer
Research, were maintained in Iscove’s Modified Dubelcco’s Medium, supplemented with 10%
inactivated fetal calf serum, 2.0 mM glutamine, 100 units/mL penicillin and 100 units/mL
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streptomycin. The cells were incubated at 37 °C in an environment containing 5% CO2. Cells
were passaged weekly and harvested using a mixture of 0.25% trypsin and 0.53 mM EDTA in
Hank’s Buffered Salt Solution without calcium or magnesium.

4.4.15 Pretargeted PET Imaging Experiments
All pretargeted PET imaging experiments were performed on a Focus 120 microPET
scanner (Siemens Healthcare Global). Female athymic nude mice (n=5) bearing subcutaneous
SW1222 xenografts on their right shoulder (9 days post-inoculation) were intravenously injected
with either 100 μg (0.66 nmol) or 15 μg (0.10 nmol) of either sshuA33-Ygg or sshuA33-TCO
(150 μL in 0.9% sterile saline). After an accumulation interval of 120 hours they were then
administered 16.7 MBq (450 μCi) of [64Cu]Cu-SarAr-Tz (0.75 nmol). Approximately 5 minutes
prior to imaging, mice were anaesthetized by inhalation of 2% isoflurane gas (Baxter Healthcare,
Deerfield, IL) and air gas mixture, and placed on the scanner bed. Isoflurane was maintained at
2% for the duration of the scan. Static scans were taken at prescribed time points (4 h and 24 h)
following injection of radioligand for a 15 min. total scan time. An energy window of 350−700
keV and a coincidence timing window of 6 ns were used. Data were sorted into 2-dimensional
histograms by Fourier rebinning, and images were then reconstructed using a two-dimensional
ordered subset expectation maximization (2DOSEM) algorithm (16 subsets, 4 iterations) into a
128 × 128 × 159 (0.78 × 0.78 × 0.80 mm) matrix. Image data was normalized to correct for nonuniformity of response of the PET, dead-time count losses, positron branching ratio, and physical
decay to the time of injection. However, no attenuation, scatter, or partial-volume averaging
corrections were applied. Activity concentrations (percentage of injected dose per gram of tissue
[%ID/g]) and maximum intensity projections were determined by conversion of the counting
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rates from the reconstructed images. All resulting PET images were analyzed using ASIPro VM
software.

4.4.16 Pretargeted Biodistribution Experiments
Following PET imaging or blood half-life experiments, mice were euthanized according to
MSKCC Institutional Animal Care and Use Committee-approved protocols by inhalation of CO2
gas for 5 minutes. Tissues were then removed, allowed to air-dry for 5 minutes, then weighed
and placed on a gamma counter. Counts were corrected to activity using a calibration curve
generated from known standards of

64

Cu or

89

Zr.

Activity was then decay-corrected and

normalized to percent injected dose per gram. PET images were acquired at 24 h post-injection
of

89

Zr-labeled immunoconjugates for a 10 min total scan time. Scan data were treated as

described above.
15 µg Tumor:Tissue Ratios
Average
Ygg
TCO
t-test
Tumor:Blood
7.4 ± 1.8
4.5 ± 1.7
**
Tumor:Liver
5.1 ± 1.1
2.4 ± 0.8
**
Tumor:Spleen
12.1 ±2.6
5.7 ± 2.1
**
Tumor:Small Intestine 30.3 ± 7.5 15.8 ± 5.8
*
Tumor:Large Intestine 39 ± 10.4 17.5 ± 7.5 ***
Tumor:Kidney
2.1 ± 0.7
1.1 ± 0.4
*
Tumor:Muscle
52.7 ± 10.8 27.9 ± 10.1 ***

Figure 4.7: Low-dose preinjection tumor-to-tissue ratios.

4.4.17 Blood Serum Half-Life
Female athymic nude mice (n=5) not bearing tumors were administered ~60 µCi (1.5 µCi/µg) of
one of the following

89

Zr-labeled antibodies by tail-vein injection: DFO-sshuA33-Ygg-TCO,
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DFO-sshuA33-TCO, DFO-huA33, DFO-endoS-huA33, or DFO-sshuA33-Ygg-NH2. Following a
prescribed time after injection (2, 6, 24, 48, 72, 120, and 144 h), blood was collected with a glass
capillary tube from the tail vein contralateral to that originally injected. Capillary tubes were
placed in tubes, weighed, and counted for activity on a gamma counter. Activity was then
decay-corrected and normalized to percent injected dose per gram of blood. PET images were
collected after 24 h (Figure 4.8).

Figure 4.8: Healthy athymic nude mice administered [89Zr]Zr-DFO-labeled huA33
immunoconjugates and imaged by PET 24 h later.

Blood serum half-lives for each construct were calculated by fitting a bi-exponential decay curve
to %ID/g and blood-draw time values. This accounted for a short serum half-life during the
period immediately following injection (ta), as well as a long serum half-life during the terminal
phase of clearance (tb). The program Prism 7TM was used to calculate both half-lives and their
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relative contributions to the overall half-life (in %). Both half-lives were weighted based on their
relative contributions using the following formula:

Values for antibody half-lives are summarized in the table below:
Construct

t1/2

tb (slow) [hour]

ta (fast) [hour]

% fast

huA33-Ygg-TCO

77.7

85.1

3.2

52.9

huA33-PEG12-TCO

29.8

33.0

3.0

54.7

huA33

20.7

37.1

7.0

53.9

EndoS-huA33

58.9

63.5

2.0

55.9

huA33-Ygg-NH2

33.9

41.2

2.8

48.8

ss
ss

ss

Figure 4.9: Blood serum half-lives of various huA33 constructs.

4.4.18 Xenograft Models
Female athymic nude mice (6-8 weeks old) were obtained from Charles River
Laboratories (Wilmington, MA) and allowed to acclimatize for approximately 1 week prior to
inoculation. They were housed in ventilated cages and provided food and water as needed. They
were anaesthetized using a mixture of 2% isofluorane (Baxter Healthcare, Deerfield, IL) and
oxygen gas for 5 minutes before being moved to the table where isoflurane was maintained for
the duration of procedure.

Tumors were induced by the subcutaneous injection of 5x106

SW1222 cells suspended 150 μL of a 1:1 mixture of cell media and Matrigel Matrix (Corning
Life Sciences).

The tumors reached the ideal size for imaging (~100-150 cm3) after

approximately 14 days.
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4.4.19 Statistical Analysis
Comparing differences between two values was performed using a paired Student’s t-test,
where significance was evaluated at P<0.05.

Calculations were performed using the Data

Analysis plugin for Microsoft Excel.
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Chapter 5: Pretargeted PET Imaging of Bone
The following work was supported in part by the Education and Research Foundation of the
Society of Nuclear Medicine and Molecular Imaging.

5.1 Introduction
Pretargeting has emerged in recent years as an exciting alternative to directly-labeled
radioimmunoconjugates.16,
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The long circulation time of IgGs and other macromolecules

necessitates their pairing with isotopes that have comparable half-lives (89Zr, 124I, etc.), resulting
in a significant – and potentially harmful – radiation dose to the patient. Pretargeting separates
injection of the TCO-bearing antibody from the Tz-bearing radioligand, allowing ample time for
antibody to accumulate at regions of interest while clearing from non-target organs. When the
radioligand is injected it is able to swiftly find and ‘click’ to the antibody, localizing in regions of
high antigen expression.

The fast pharmacokinetics of the radioligand enables the use of

radionuclides with shorter half-lives (64Cu,

68

Ga,

18

F, etc.), reducing the overall dose to the

patient. Recent work has focused on the development of novel tetrazine-bearing radioligands, as
well as different methods for the attachment of trans-cyclooctene to antibodies.16, 51, 52, 89
In the preceding chapters, we describe the development and optimization of a
methodology for the pretargeted PET imaging of a colorectal cancer using a TCO-bearing huA33
antibody and a novel tetrazine-containing radioligand, [64Cu]Cu-SarAr-Tz (Figure 5.2A).51,

89

We have demonstrated that this approach enables the rapid and precise delineation of tumor
tissue with minimal background uptake in murine models of colorectal carcinoma and believe
that this strategy is an excellent candidate for translation to the clinic. Perhaps the most pressing
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reason to test pretargeting in larger mammals is the inescapable size difference between mice and
men. While the IEDDA click reaction is extremely fast, its kinetics rely on the ability of the TCO
and Tz to find one another. This has been shown to occur in two milliliters of mouse blood;
whether the same will suffice in five and a half liters of flowing human blood has yet to be
shown. It is therefore sensible to try an intermediately-sized species before progressing.

Figure 5.1: Bone pretargeting schematic showing 1) injection and localization of TCO-BP within
the bone and 2) its rapid clearance from non-target tissue; 3) injection of Tz-bearing radioligand
and its binding to exposed TCO; 4) rapid clearance of radioligand leaving activity only at the
bone.

To our knowledge, there have been no efforts to advance this technology into larger
mammals, likely due to the fact that very few cancer models exist in these species. The approach
we sought to take here circumvents this issue by using a bone-targeting trans-cyclooctene-
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bisphosphonate construct (TCO-BP) rather than a tumor-targeting moiety, as illustrated in Figure
5.1.92 Given the prevalence of bone in mammalian species, we are able to inject this in lieu of an
antibody-based vector (1), allowing time for it to accumulate in the skeleton of the subject. After
a period of time, most, if not all, of the TCO-BP will have been integrated into the bone (2);
making the highest concentrations of TCO be localized in areas of bone turnover. Following
TCO-BP incorporation with an injection of [64Cu]Cu-SarAr-Tz (3), we would allow the ligand to
passively seek out and bind to TCO groups present in the subject. The “clicking” between the
Tz-bearing radioligand and the TCO-BP therefore confines the radioactivity to areas of high
bone turnover and remodeling (4). It was for this reason that relatively short preinjection
intervals (<6 hours) were selected for these experiments.

5.2 Development of TCO-BP
The bone targeting agent TCO-BP was initially conceptualized and tested by Yazdani, et
al. with Tz-radioligands binding SPECT imaging (99mTc) and radiotherapeutic (177Lu) isotopes
(Figure 5.2).93 A derivative of alendronic acid (a common bisphosphonate for treatment of
degenerative bone disorders) TCO-BP binds initially to the mineral hydroxyapatite – a
component of hard bone structure. Osteoclasts remodel the bone in areas of high mechanical
stress by leaching calcium ions through acidification of the surrounding microenvironment. The
change is pH also has the effect of desorbing TCO-BP from the hydroxyapatite. Once freed, it
acts on the ruffled border of the osteoclasts, increasing the “leakiness” of the membrane to Ca2+
and H+ ions.94 When administered in therapeutic doses, alendronic acid acts in this way to halt
bone resorption without observable toxicity to the osteoclasts themselves. While it is not yet
clear at what point TCO-BP is able to react with Tz-radioligands, results by Yazdani et al.
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demonstrate that longer preinjection intervals drastically reduce bone uptake of the radioligand,
suggesting that some metabolism or occlusion of the TCO occurs over time.

Figure 5.2: Structures of [64Cu]Cu-SarAr-Tz (A) and TCO-BP (B).

5.3 Biodistributions
The initial work describing TCO-BP focused on SPECT isotopes, prompting us to test it
with our highly effective ligand [64Cu]Cu-SarAr-Tz for PET imaging. To this end, two cohorts of
healthy non-tumor bearing female Balb/c mice were administered a preinjection of TCO-BP (200
µL, 2.5g/L in 0.9% sterile saline, 1.2 µmol). Next, either 1 or 6 hours later [64Cu]Cu-SarAr-Tz
was injected (250 µCi, 0.78 nmol) and mice from each cohort were sacrificed at 6 and 24 hours
post-injection of radioactivity. Organs were harvested, weighed, and counted on a gamma
counter (Figure 5.3).
Between both 1 and 6 hour preinjections of TCO-BP, the bone demonstrated the highest
uptake-per-gram of all other organs, with the 6 h preinjection showing 23.6 ± 1.4 %ID/g at 24 h
post-injection of radiation. Higher retention in the kidneys, seen here, is characteristic of the
radioligand, [64Cu]Cu-SarAr-Tz. Other organs displaying higher uptake, such as the liver and
spleen may be the result of accumulated TCO-BP.95 While the six-hour preinjection of TCO-BP
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had higher uptake in the bone than a one-hour preinjection, for subsequent studies the shorter
interval was chosen because uptake was still dramatic and eventual studies in dogs required a
much stricter and shorter experimental timeline.

Figure 5.3: Pretargeted biodistribution in healthy Balb/c mice of TCO-BP followed 1 or 6 hours
later with [64Cu]Cu-SarAr-Tz. Mice were sacrificed 6 and 24 h after injection of the radioligand.

5.4 PET Imaging
Following the success of the biodistribution, a 1 h preinjection interval was chosen for
the subsequent PET imaging study.

Again, healthy, female Balb/c mice were injected

intravenously with TCO-BP (200 µL, 2.5g/L in 0.9% sterile saline, 1.2 µmol). 1 hour later,
[64Cu]Cu-SarAr-Tz was injected (400 µCi, 0.78 nmol) and PET/CT imaging was performed 1,
6, and 24 h following injection of the radiotracer (Figure 5.4). Furthermore, femurs were
removed from the mice following the 24 h imaging time point and flash-frozen in OCT
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compound (Scigen, Gardena, CA). Femurs were then cut by cryotome into 0.8 µm sections and
mounted on clear sticky tape. Autoradiography was performed and images obtained via a bright
field lens and images were overlaid in Adobe Photoshop (Figure 5.5).
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Figure 5.4: Pretargeted PET imaging in healthy Balb/c mice of TCO-BP followed 1 hour later
with [64Cu]Cu-SarAr-Tz. PET/CT overlay shows bone attenuation in white and radioactivity in
yellow.
PET images obtained serve to validate the biodistribution data obtained previously, as
bone uptake is clearly observed at all time points, even as early as 1 hour post-injection of
radioligands. Unbound radioligand can be seen to clear rapidly through the renal system as the
bladder is visible at 1 h. It is important to note the areas of highest uptake seem to be the joints,
areas of high bone-turnover that are known targets of bisphosphonates. This observation is
sustained in the autoradiography, where the ends of the joints have the highest uptake of
radioactivity. These images also serve to confirm that administered radioligand is localized in
the hard structure of the bone rather than in the marrow.

Figure 5.5: Overlay of mouse femur autoradiography and bright-field images.
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5.5 Bone Pretargeting in Dogs
Concluding successful testing of bone pretargeting with TCO-BP and [64Cu]Cu-SarAr-Tz
in mice, we set to test this system in dogs afflicted with osteosarcoma. Subjects will be
administered an I.V. injection of TCO-BP (5 mg/kg), followed 6 hours later by 5 mCi of
[64Cu]Cu-SarAr-Tz (S.A. 800-900 μCi/μg) in 0.9% sterile saline. Subjects will be monitored by
PET imaging for an initial 30 minute dynamic scan followed by another static scan at 4 h p. i.

5.6 Conclusion
A pretargeting methodology using the IEDDA click reaction between a Tz and TCO
shows great promise in reducing radioactive dose to patients. The development of a TCObisphosphonate allowed us to test our ligand, Tz-SarAr, for bone pretargeting. With a 1 h
preinjection interval we were able to demonstrate clear bone uptake with minimal retention in
background organs.

Furthermore, autoradiography and histology allowed us to prove

radioligand uptake was occurring within the hard structure of the bone rather than the marrow.
We eagerly await the completion of testing within dogs as it will be an important preclinical
milestone for pretargeted PET imaging.
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Chapter 6: Evaluation of Coiled-Coil Heterodimers for In Vivo
Ligation

6.1 Introduction
One early and prominent form of pretargeting capitalized on the highly specific and
strong affinity between biotin, an essential coenzyme, and streptavidin, a bacterially expressed
tetrameric protein capable of binding one biotin per monomer. Such pretargeting systems proved
effective at reducing radioactive dose to healthy tissue and several clinical trials were initiated to
test its efficacy in patients. Unfortunately, streptavidin/biotin pretargeting suffered a fatal flaw:
the bacterial origin of streptavidin produced immune responses in patients, precluding repeated
administrations. In the early 2000s, Moll et al. published a paper in which they offered an
alternative to streptavidin/biotin pretargeting.96 After developing a coiled-coil heterodimer with
strong binding affinity they suggested that utilization of these peptides could serve as the basis
for a new form of pretargeting. The structures they describe were found to have Kd values on the
order of 10-15 M, very similar to that of streptavidin/biotin binding.97 Of particular interest is the
lack of known leucine zippers present in the blood or on the surface of cell membranes that could
interfere with their use in pretargeting.
Leucine zippers are a coiled-coil structural component found in some proteins.
Fundamentally, they are a coiled pair of α-helices with sequences producing a domain of
hydrophobic residues (often leucine) that allow for dimerization between the two coils.
Common design features include a heptad (7-residue) repeat, with positions “a” and “d” dictating
the inter-helix interactions (Figure 6.1). In an effort to minimize homodimerization, sequences
can be designed as complementary acidic/basic pairs. Such pairings can stabilize heterodimers
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through the formation of anion/cation salt bridges, while destabilizing homodimer formation
through electrostatic repulsion.98

Figure 6.1: ZIP pretargeting showing one heterodimeric peptide bound to the antibody and its
counterpart bound to the radioligand. The two should dimerize in vivo, effectively binding the
antibody and radioligand together.

Furthermore, by designing the sequences with a degree of asymmetry, coil-coil
interactions can be directed to bind in a parallel fashion over antiparallel. There are a number of
such leucine zipper sequences that have been used for the construction of chimeric proteins 99 as
well as antigen cross-linking therapy

100

and extensively for intracellular delivery by membrane

fusion.101-103 Despite nearly two-decades of research, however, no work has been performed
implementing leucine zippers for radionuclidic pretargeting as originally suggested by Moll et al.
The goal of this project was to provide preliminary data investigating the efficacy of so-called
“ZIP pretargeting”.
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While some other leucine zippers have been tested preliminarily in vivo, we have chosen
to proceed with sequences similar to those suggested in 2001, but modified slightly to include an
additional salt bridge (Figure 6.2).104 The primary benefit of this sequence is its lack of lysine
residues, a common feature in other leucine zippers. This allows us to modify the N-terminus of
each peptide in a facile one-step synthesis without the need for a deprotection step. The
sequences are denoted as ZR, the basic sequence, and ZE, the acidic sequence.

Figure 6.2: Leucine zipper structure with sequences of ZE and ZR. (Top) top-down view of
leucine zippers with a-g and a’-g’ representing amino acids in a helical structure. Every seven
residues corresponds with 2 full rotations. (Bottom) sequences of ZR and ZE with letters
corresponding to diagram above. Red denotes hydrophobic residues while blue denotes charged
residues for electrostatic interactions.
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6.2 Coupling of ZIP Peptides
Once the sequences for the leucine zipper were chosen, it was necessary to independently
evaluate their binding. Peptide ZE and ZR were purchased from CSBio and their mass and
purity (>95%) verified by HPLC and LCMS.
6.2.1 Gel Electrophoresis of ZR/ZE
3 µL aliquots of ZR, ZE, and 1:1 ZR/ZE (2 g/L in PBS, 0.4 mM) were mixed with 17 µL
of Native Tris-Glycine Sample Buffer (ThermoFisher). A 3-12% Bis-Tris native gel was loaded
with 17 µL of sample per well, and 15 µL of native protein ladder. Gel was run at 4 °C and 55 V
for 24 hours in Tris-Glycine Native Running Buffer (ThermoFisher), then washed 3x with water,
stained for 1.5 hours in SimplyBlue Safe Stain, and destained overnight in water.
Gel electrophoresis under native conditions proved effective as an initial method to
determine ZR/ZE dimerization.

Running at a low voltage in cold conditions effectively

separated the dimerized bands from the lone peptide, showing clearly larger structures in the
ZR+ZE band over the ZE band alone (Figure 6.3). ZR did not show any staining possibly due to
the sequence’s overall positive charge. Also of note is the presence of two lower mobility bands
in the ZE+ZR lane. This suggests some higher order interactions beyond hetrodimerization.
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Figure 6.3: Native PAGE gel showing ZR, ZE, and a mixture of ZR and ZE. ZR does not stain
with traditional methods and so is not visible. The lane with ZR+ZE shows three bands: the
lowest likely being unbound ZE, and the other two being supramolecular organization of the
peptides.

6.2.2 Circular Dichroism (CD) Spectroscopy
Circular dichroism (CD) spectroscopy measures the interactions of molecules with
circularly polarized light, called ellipticity. With respect to biological molecules, ellipticity often
corresponds with higher-order structures within proteins, such as alpha-helices and beta sheets.
Samples of ZR and ZE were prepared in PBS (pH 7.4) at a concentration of 0.4 mM while
ZR+ZE was prepared by mixing 0.4 mM solutions of ZR and ZE in a 1:1 molar ratio, such that
each peptide was present in solution at 0.2mM. All samples and a PBS blank were run on a CD
spectrometer in cuvettes with a 2 mm path length. PBS background absorbance was subtracted
manually and results were corrected for concentration differences according to Beer’s law:
Absorbance
where ε is the molar absorptivity, l is the path length of the cuvette, and c is the concentration of
solution. The results (Figure 6.4) show ZR as having no ordered structure, while ZE alone
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exhibits a spectrum characteristic of an alpha helix. The mixture of ZR and ZE together shows a
much more prominent signal suggesting that a more ordered alpha helix is forming than ZE
alone. Overall, these results correlate very closely with those originally presented by Moll et al.
for a similar leucine zipper sequence.96 The signal exhibited by ZE suggests that there may be
some homodimerization occurring, a conclusion further corroborated by MALDI-TOF data that
is discussed later.

Figure 6.4: Circular dichroism spectroscopy of ZR, ZE, and a mixture of ZR and ZE.

6.2.3 Size Exclusion Chromatography
In an effort to better visualize the multiple bands that were appearing on native gels,
samples were run on a Superdex 75 Increase (10/300) size exclusion column. Samples were
injected as 30 µL (0.2 mM in PBS) and run at a flow rate of 1 mL/min with PBS (pH 7.4) as the
mobile phase. The solitary peptides each eluted at different times, ZR at 14.6 min and ZE at 12.5
min (Figure 6.5). The peptides are identical in length and very similar in molecular weight,
making this drastic difference surprising. Considering also the alpha helical character observed
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for ZE in the CD spectrum, this further supports the hypothesis that ZE orients into some ordered
structure producing a larger hydrodynamic radius than the ZR peptide. The mixture of ~1:1
ZE+ZR eluted at 13.2 min and was clearly differentiated from the free peptides alone.

Figure 6.5: Size-exclusion chromatography of ZR, ZE and a mixture of ZR and ZE.

6.2.4 MALDI-ToF Mass Spectrometry of ZR + ZE
Samples of ZR, ZE, and 1:1 ZR/ZE were submitted for MALDI-TOF mass spectrometry
(Figure 6.6). Results confirmed heterodimerization was occurring in the ZR/ZE sample with the
presence of a peak with mass equal to ZR+ZE. Also seen in ZR/ZE was the presence of the
homodimer ZE x 2 mass.

It is as-yet unclear whether this will interfere with ZR+ZE

dimerization. The sample of ZE also exhibited a homodimerization peak - a feature not found in
the ZR sample. These data, in conjunction with others above, were promising and suggested that
the leucine zipper peptides could indeed be used for pretargeting.
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Sample
ZR
ZE
ZR + ZE

MALDI-ToF
Masses Observed Peak Identity
Expected Mass
5180.41 ZR monomer
5180.94
4946.98 ZE monomer
4947.37
9891.97 ZE homodimer
9894.74
4948.5 ZE monomer
4947.37
5181.5 ZR monomer
5180.94
9894.8 ZE homodimer
9894.74
10128.1 ZR/ZE heterodimer
10128.31

Figure 6.6: Summary of MALDI-ToF peaks for ZR and ZE.

6.3 Functionalizing ZIP Peptides
Leucine zipper peptides ZR and ZE were modified by N-terminal nucleophilic
substitutions with NHS-ester bearing ligands (Figure 6.7). Previously published experiments
with these sequences place the ZR peptide on the antibody.102 Given our data suggesting ZE
forms a homodimer in solution, we decided to follow suit, at least until new data suggest
otherwise.

Figure 6.7: Functionalizing zipper peptides. A) ZR-DBCO; B) ZE-AF680; C) ZE-NOTA.
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6.3.1 Synthesis of ZE-AF680
The sequence ZE was modified to bear an AF680 fluorescent dye in order to optically
quantify its binding to a ZR-modified antibody (Figure 6.7B). To this end, 1 mg of ZE was
dissolved in DMSO (125 µL, 8 g/L) and reduced using 25 molar equivalents of N,Ndiisopropylethylamine (0.88 µL, 742 g/L). Next, 3 molar equivalents of AF680-NHS was added
(17.4 µL, 33.3 g/L in DMSO), DMSO added to a final volume of 500 µL, and the solution
allowed to mix at 25 °C for 24 h. The product was collected by C18 reverse-phase preparative
HPLC (r.t. = 29.0 min), frozen and lyophilized in the dark, resulting in 1.0 mg of blue solid (85
%yield). Product was dissolved in 250 mM NaOH in water, as conjugate displayed poor
solubility at acidic pH. LCMS confirmed synthesis (ESI+): calculated for C240H389BrN61O86S3,
5784.63; found m/z 1448.0 (M+7H)4+.

6.3.2 Synthesis of ZE-NOTA
The sequence ZE was modified to bear a NOTA moiety as a preliminary

64

Cu chelator

for pretargeting studies (Figure 6.7C). To this end, 5.6 mg of ZE was dissolved in water (10
g/L) and the pH adjusted to 10.0 using Na2CO3 (1 M). Next, 5 molar equivalents of p-SCN-BnNOTA were added (63.7 µL, 40 g/L in DMSO), water was added to a final volume of 800 µL,
and the solution allowed to mix at 37 °C for 48 h. The product was collected by C18 reversephase semi-preparative HPLC in a gradient of 5:95 ACN/H2O to 95:5 ACN/H2O (both solvents
with 0.1% TFA) over 30 min at a flow rate of 6 mL/min (r.t. = 20.0 min). Eluent was frozen and
lyophilized, resulting in 3.45 mg of white powder (57 %yield). LCMS confirmed synthesis
(ESI+): calculated for C234H372N62O82S, 5394.66; found m/z 1351.0 (M+10H)4+.
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6.3.3 Radiolabeling of ZE-NOTA
Chelation of 64Cu by ZE-NOTA was tested under previously published conditions.16 An
aliquot of ZE-NOTA (0.7 µL, 0.3 mM in DMSO) was diluted in 100 µL NH4OAc buffer (0.1 M,
pH 4.5). Next, 100 µCi of [64Cu]CuCl2 (20 µL in 0.1 M HCl) was added and the reaction
allowed to mix at 25 °C for 30 min. Successful radiolabeling (>99% RCY) was evaluated by
radioHPLC using an analytical reverse-phase C18 column, eluted with a gradient of 5:95
ACN/H2O (both solvents with 0.1% TFA) to 95:5 ACN/H2O over 30 min at 1 mL/min (r.t. 11
min). ZE alone did not associate with 64Cu under these conditions.

6.3.4 Synthesis of ZR-PEG5-DBCO
The sequence ZR was modified to bear a PEG5-DBCO moiety to facilitate its conjugation
to an azide-modified antibody (Figure 6.7A). To this end, 4.0 mg of ZE was dissolved in DMSO
(8 g/L) and reduced using 25 molar equivalents of N,N-diisopropylethylamine (3.4 µL, 742 g/L).
Next, 5 molar equivalents of DBCO-PEG5-NHS was added (335 µL, 8 g/L in DMSO), DMSO
added to a final volume of 500 µL, and the solution allowed to mix at 25 °C for 24 h. The
product was collected by C18 reverse-phase semi-preparative HPLC in a gradient of 30:70
ACN/H2O to 70:30 ACN/H2O (both solvents with 0.1% TFA) over 30 min at a flow rate of 2.5
mL/min (r.t. = 15.8 min). Eluent was frozen and lyophilized in the dark, resulting in 0.9 mg of
orange solid (21 %yield). LCMS confirmed synthesis (ESI+): calculated for C 253H419N83O71,
5756.17; found m/z 1152.0 (M+4H)5+.
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6.4 Antibody Ligation
Trastuzumab was chosen as the initial antibody with which to test “zipping” between the
two peptide-conjugates due to its well-characterized structure and ready availability to our lab.

Figure 6.8: A) Non-site-specific labeling of Trastuzumab with PEG4-N3; B) conjugation of
ns
Tras-N3 with DBCO-ZR.

6.4.1 Synthesis of nsTrastuzumab-PEG4-N3
As a preliminary method of antibody conjugation, PEGylated azide moieties were
conjugated to trastuzumab (Tras) in a non-site-specific manner using N3-PEG4-NHS (Figure
6.8A).

Initial aliquots of Tras are passed through two consecutive size exclusion

chromatography columns to remove any storage buffer (Sephadex G-25 M, PD-10 column, GE
Healthcare), eluted with PBS (pH 7.4) and concentrated intermittently using centrifugal filtration
units with a 50,000 molecular weight cut-off (AmiconTM Ultra, Millipore Corp., Billerca, MA).
A 2 mg aliquot of this purified Tras (6.4 g/L, 13 nmol) is diluted to 2 g/L in PBS and the buffer
pH adjusted to 8.7 using Na2CO3 (0.1 M). A 10-fold molar excess of N3-PEG4-NHS (64 mM in
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DMSO, m.w. 388.37) was added and the mixture and allowed to mix at 25 °C for 1 h. The
mixture was then purified by size exclusion chromatography columns to remove unreacted
ligand, eluted with PBS (pH 7.4) and concentrated using centrifugal filtration units with a 50,000
molecular weight cut-off. The number of bound azides was quantified through a degree of
labeling using a fluorescent dye labeled with DBCO (MB488-DBCO). A 50 µg aliquot of
ns

Tras-PEG4-N3 (0.3 nmol) was diluted to 450 µL in PBS (pH 7.4) and mixed with 20 µL of

MB488-DBCO (8.4 mM in DMSO, 169 nmol). The resultant mixture was set overnight on a
thermomixer in the dark at 25 °C and purified the next day by a PD-10 size exclusion column.
The Tras-MB488 eluent was concentrated by centrifugal spin filter and the ratio of MB 488 dye
per Tras ratio quantified by UV-vis spectrophotometry. The final construct was found to have
4.0 dyes/mAb.

6.4.2 Synthesis of nsTrastuzumab-ZR, “Tras-ZR”
To facilitate SPAAC ligation of ZR-PEG4-DBCO to Tras-PEG4-N3, 4.3 µL of ZR-DBCO
(2 mM in DMSO, 6.6 nmol) was diluted in 30 µL PBS, then mixed with a 0.5 mg aliquot of
ns

Tras-PEG4-N3 (3.4 g/L in PBS, 3.3 nmol) (Figure 6.8B). The resulting mixture was set to mix

for 24 h at 25 °C and purified the next day by a PD-10 size exclusion column. Recovered nsTrasZR was found to be 415 µg (83% yield). A degree of labeling quantification using a method
identical to that described above showed 3.0 MB488 dye/mAb. We can approximate then that 1
ZR ligand was conjugated per trastuzumab through this method.
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6.5 Leucine Zipper Binding
With successful synthesis of ZE ligands and an antibody-bound ZR, we were then able to
test the ability of ZE and ZR to “zip” in vitro. Initial attempts to separate free ligand by PD-10
were unsuccessful, with unbound ligand eluting at a similar volume to antibody. It is possible
that the ZE conjugate is simply too large to be separated in this method, or there could be nonspecific association of the ligand to the antibody rather than its ZR counterpart.

6.5.1 Native Gel Electrophoresis of Zipper Conjugates
With the success of native PAGE to visualize leucine zipper binding, we set out to test
binding of the conjugates using a similar method. The following samples were loaded as 17 µL
each (5 µL of sample + 15 µL of tris-glycine native sample buffer) onto a 4-16% Bis-Tris native
gel: ZE-AF680 (1.5 µg), Tras-ZR + ZE-AF680 (appx. 1:2 molar ratio, 1 µg mAb), Tras-PEG4-N3
(0.7 µg), Tras-PEG4-N3 + ZE-AF680 (appx. 1:2 molar ratio, 1 µg mAb). Gel was run at 55 V
overnight, washed 3x in water, then immediately scanned at 700 nm.

The gel was then

rehydrated, removed from the scanner, and stained for 1 hour in SimplyBlue Safe Stain. Finally,
the gel was destained in water overnight and scanned again. A false-color overlay was generated
(Figure 6.9), with AF680 signal displayed in red, while stain is shown in black. The overlay
very clearly illustrates that ZE-AF680 will bind to antibody only if there is ZE present, as there is
a strong signal overlaid with nsTras-ZR, but not over nsTras-N3. Unbound ZE-AF680 moved to
the bottom of the gel.
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Figure 6.9: Native PAGE gel overlay. Black/white indicates protein stain, while red indicates
AF680 fluorescence signal.

6.6 Conclusion
The strong and selective conjugation possibilities presented by leucine zipper
heterodimers hold potential for applications in pretargeted imaging. In this investigative project,
we demonstrate that the complementary sequences ZE and ZR show rapid dimerization that can
be effectively characterized through a variety of methods. Strong alpha-helical character was
observed through CD spectroscopy in a mixture of ZE/ZR which was not present when each
homodimer was measured alone. This ordered coupling could also be observed in size-exclusion
chromatography and MALDI-TOF mass spectrometry studies.

In particular, native gel

electrophoresis was able to demonstrate that specific antibody “zipping” can be used to attach a
fluorescent dye-bearing-ZE to a ZR-coupled antibody. Initial steps have been taken to adapt
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these ligands for radiochemical use, and their testing will serve as the next step in developing
this project.
Care should be taken in moving forward, however, as there is an unanswered question
relating to the apparent homodimerization of the ZE sequence. Whether this will interfere
withpretargeting or influence pharmacokinetics has yet to be seen. Furthermore, these sequences
have not yet been examined in vivo and it is unclear how these long-chain peptide sequences will
behave when exposed to other globular proteins and enzymes. That being said, this is an
exciting and promising route of exploration with applications in radionuclide delivery.
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Chapter 7: Introduction to Enzyme-Responsive Self-Assembling
Peptide Amphiphiles
This project was supported in part by the Tow Research Foundation.

7.1 Introduction
In this second part of my dissertation, I explore a project that aims to exploit the
expression of an extracellular enzyme MMP-9 using self-assembling peptide amphiphiles
(SAPA). The over-expression of matrix metalloproteinase 9 (MMP-9) has been well-established
as a biomarker for invasive, aggressive, and metastatic prostate cancer. As a result, tools which
could provide physicians with a non-invasive means to determine MMP-9 levels in tumors could
be invaluable for the diagnosis and management of these malignancies. Self-assembled peptide
amphiphiles (SAPA) offer a particularly promising platform for the creation of MMP-9-sensitive
imaging agents, as MMP-9 cleavage sites can be built into the sequence of the peptidic
monomers to make the self-assembled nanostructures enzyme-responsive. The basic principle of
the imaging agent is straightforward: in the absence of MMP-9, the
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Zr-labeled SAPA (89Zr-

SAPA) will persist in its micellar form and therefore clear from the body. However, when the
89

Zr-SAPA encounters MMP-9 on the surface of a prostate cancer cell, its peptide subunits will

be cleaved, and it will undergo a morphological micelle-to-fiber transition that will immobilize it
on or near the surface of the cell and lead to the selective accumulation of radioactivity in the
MMP-9-expressing tumor (Figure 7.1).
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Figure 7.1: Schematic of targeting MMP-9 with a radiolabeled SAPA for PET imaging.

7.1.1 Self-Assembling Peptide Amphiphiles
The last decade has witnessed an explosion of research surrounding the development of
nanoparticles for biomedical applications.105

Such particles have demonstrated particular

efficacy in encapsulating chemotherapeutics and radioisotopes, facilitating their delivery to
cancer cells. There have been several different approaches to delivering these particles in vivo.
One particularly intriguing approach has been the development of enzyme-responsive “soft”
nanomaterials built from enzyme-cleavable peptide amphiphiles.106,
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With a massive

catalogue of both natural and unnatural amino acids that exhibit a wide range of different
chemical properties, peptides can be “programmed” to behave in a variety of different ways. For
instance, the sequence of these peptide amphiphiles can be tuned to mimic the natural affinity of
certain peptidase substrates.108, 109 The peptidase of interest can then recognize and cleave the
sequence at this designated site, inducing a change in supramolecular structure.110 This built-in
morphological switch allows the peptide micelle to maintain its structure in the absence of the
target enzyme while traveling through blood circulation. However, when the target enzyme is
encountered, the switch is activated and the micelle undergoes a structural transition from
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spherical micelle to fiber. Use of this system has been demonstrated previously to effectively
deliver drugs to sites of enzymatic activity.109, 111, 112

7.1.2 MMP-9 Targeting
Matrix metalloproteinase-9 (MMP-9) is an excellent candidate for targeting by
radiolabeled SAPAs. MMPs are a family of zinc endopeptidases secreted into the extracellular
space and are involved in the degredation of the extracellular matrix.113

MMPs are

overexpressed in a number of diseased states, including aggressive, metastatic cancer. The target
for this study, MMP-9, has been correlated with increased disease progression, metastatic spread,
tumor aggressiveness, and poor prognosis particularly in prostate cancer.114 The need exists then
for modalities to image MMP-9 activity non-invasively to better allow clinicians to determine
aggressiveness of disease without the need for invasive and frequently unreliable biopsies.

7.1.3 PET Imaging with 89Zr-Labeled Micelles
The use of nanoparticles for the delivery of PET radionuclides shows great promise, as
PET can provide important quantitative information that complements the anatomical maps
generated by computed tomography (CT) and magnetic resonance imaging (MRI). Pairing
radionuclides of appropriate physical half-lives to the physiological half-lives of the chosen
vector is crucial to the development of effective imaging agents. For this reason,
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Zr (t1/2 ~3.2

days) and its acyclic chelator deferoxamine (DFO) are a good match for radiolabeled
nanostructures which typically have long circulation times in vivo. By attaching the radiometal
and its chelator to the amphiphile’s hydrophobic block we sought to capitalize on the post99

cleavage fiber formation in an effort to localize the radioactivity near the site of enzyme activity
(Figure 7.2).

Figure 7.2: Synthesis of [89Zr]Zr-DFO-SAPA.

7.1.4 Substrate Selection
Selection of sequences took into consideration both enzyme recognition and potential for
self-assembly. We discuss three primary sequences (Figure 7.3) selected, in two cases (GD and
GLK), for their rapid cleavage by MMP-9, micelle formation, and secondary post-cleavage
structure.112 The third peptide (FFD) was chosen in contrast to the other two as a MMP-9recognition negative sequence.
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Figure 7.3: Peptide amphiphiles A) FFD and DFO-FFD, B) GD and DFO-GD, C) GLK and
DFO-GLK. Red lines denote site of observed MMP-9 cleavage.
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Chapter 8: Radiolabeling Self-Assembling Peptide Amphiphiles for
PET Imaging

8.1 Enzyme Unresponsive Sequence: FFD
While the overall goal of this project was to develop radiolabeled MMP-9-cleavable
micelles, it was deemed necessary to have unresponsive micelles as well. These micelles would
serve as a negative control, as well as a platform to test labeling methods and analytical
procedures.

To this end, we chose a simple amphiphilic peptide with the sequence

FFAAAADDDD, nicknamed “FFD”. The chelator deferoxamine was chosen to bin 89Zr for PET
imaging tests. The N-terminus of the peptide resides on the hydrophobic end of the sequence,
theoretically orienting the chelated radiometal towards the center of the micelle (Figure
7.2Figure 7.2: Synthesis of [89Zr]Zr-DFO-SAPA.).

8.1.1 Synthesis of DFO-FFD
The peptide sequence FFD was modified on its N-terminus with p-SCN-Bndeferoxamine (DFO) (Figure 7.3A). First, 5.5 mg of FFD was dissolved in 1 mL DMSO (5.2
µmol, 5.2 mM) and the terminal amine deprotonated with 12 molar equivalents of TEA (8.6 µL,
720 g/L). One molar equivalent of p-SCN-Bn-DFO was then added (5.2 µmol, 31 mM in
DMSO). The reaction was mixed overnight and purified by preparative C18 reverse phase HPLC
with a gradient of 5:95 ACN/H2O (all solvents +0.1% TFA) to 95:5 ACN/H2O over 30 min and a
6 mL/min flow rate (r.t. = 22.9 min). Synthesis was verified by LCMS (ESI+); calculated for
C79H112N18O27S2, 1808.7; found m/z, 906.5 (M+4H)2+(Figure 8.1).
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Figure 8.1: LCMS of DFO-FFD validating synthesis of the intended product.

8.1.2 Atomic Force Microscopy
Testing of the self-assembly of FFD and DFO-FFD was carried out by atomic force
microscopy (AFM) and samples prepared by pipetting 20 µL of a sonicated 2 mM solution onto
a mica surface (Ted Pella, Inc.) and drying under nitrogen for 5 min. Surface maps were then
generated on a Bruker Multimode 8 AFM using the ScanAsyst PeakForce tapping mode (Figure
8.2). Samples of FFD (2 mM) produced micelles of 30-100 nm in diameter, while DFO-FFD at
2 mM did not show signs of micelle formation. Mixing FFD and DFO-FFD at a ratio of 95:5
allowed for the formation of larger micelles (~120-180 nm in diameter) while theoretically
incorporating the DFO-labeled peptides into the structure.
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Figure 8.2: AFM of FFD (2 mM) and a mixture of DFO-FFD (0.1 mM) and FFD (2 mM) plated
on a mica substrate.

8.1.3 Dynamic Light Scattering
Solutions of FFD and DFO-FFD were prepared using PBS filtered through a 0.2 µm pore
syringe filter (Waters). Dynamic light scattering (DLS) was carried out on a Zetasizer ZS
(Malvern) in a polystyrene microcuvette at 25 °C (Figure 8.3). DLS data of DFO-FFD displayed
poor polydispersity indices (typically greater than 0.5) and significant error in cumulants
analysis, suggesting that micelle structure was irregular or unstable in solution. The use of lower
concentrations tended to produce the best results, with 25-100 µM peptide concentration most
closely matching AFM results.
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Figure 8.3: DLS of DFO-FFD at 100 µM in PBS.

8.1.4 Radiolabeling of DFO-FFD
Radiolabeling of DFO-FFD was performed with 1 mCi of [89Zr]Zr-oxalate, adjusted to
pH 7.4 with Na2CO3. A 5 µL solution of DFO-FFD (5 g/L, 2.8 mM, 13.8 nmol) was added and
diluted to 150 µL with PBS. The radiolabeling solution was then mixed for 10 min at 30 °C.
Radiochemical purity was assessed at >99% by iTLC.

8.1.5 Positron Emission Imaging of Healthy Mice with [89Zr]Zr-DFO-FFD
In order to get a preliminary idea of in vivo pharmacokinetics and behavior of these
radiolabeled micelles, positron emission imaging was performed on healthy athymic nude mice
using 89Zr-radiolabeled FFD/DFO-FFD micelles. Radiolabeling of DFO-FFD was performed as
described above. Next, a 500 µCi aliquot of [89Zr]Zr-DFO-FFD was combined with 50 µL of 5
mM FFD and heavily vortexed for 1 min. The final concentration in solution was therefore 2
mM FFD and 46 µM [89Zr]Zr-DFO-FFD. Mice (n = 2) were then injected intravenously with 50
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µL doses in syringes pretreated with PBS + 1% BSA. A second cohort of mice (n=2) was
injected with a diluted volume of [89Zr]Zr-DFO-FFD (46 µM) alone in order to compare imaging
with a non-self-assembled “free” peptide. Images were then obtained 1, 6, and 24 hours postinjection (Figure 8.4).

Mice administered both mixtures demonstrated rapid hepatobiliary

clearance initially, followed by expected kidney retention at later time points.

There was

evidence as well of activity accumulation within the gall bladder. The extremely rapid clearance
through the gut may be the result of administering such highly negatively charged particles. This
clearance is typically mediated by organic anion transporter polypeptides (OATP) which are
involved in the uptake and excretion of bilirubin, a dianionic molecule, into the gallbladder.115 It
has also been seen that OATPs mediate uptake of other anionic and amphiphilic drug molecules
and are a key obstacle in successful drug design.116 This route of clearance matches well with
the observed biodistribution profile seen in the PET images, as the gallbladder is clearly visible
at 1 and 6 h. Drainage from the gallbladder into the small intestine is also seen, further
validating this hypothesis. One of the two mice administered the mixture of FFD/[89Zr]Zr-DFOFFD had some activity seemingly retained in the liver at 6 h p.i.. This liver retention, though far
from conclusive, suggested that micelles were able to form and remain stable long enough to
accumulate.117
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Figure 8.4: PET imaging of healthy anthymic nude mice administered either [89Zr]Zr-DFO-FFD
(46 µM) or micelles [FFD (2 mM)+[89Zr]Zr-DFO-FFD (46 µM)] and imaged 1, 6, and 24 h later.

8.2 Enzyme Responsive Sequences: GD and GLK
As the final goal of this project was to develop enzyme-responsive SAPA sequences, two
sequences were selected for testing. The first sequence, GFFLGLDD (abbreviated here as
“GD”), was developed initially by Kalafatovic, et al. for the selective delivery of cytotoxic drugs
to tumors.112 It has been demonstrated that near-complete digestion of GD occurs by 96 h
incubation with MMP-9.112 While this first sequence demonstrated selective delivery, a newer
sequence was developed in the interim by Jiye Son that exhibited complete MMP-9 cleavage by
24 h: FFGALGLKGK.

Here, both sequences were labeled with DFO and tested in vivo

following micelle characterization.
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8.2.1 Synthesis of DFO-GD
The peptide sequence GD was modified on its N-terminus with p-SCN-Bn-Deferoxamine
(DFO) (Figure 7.3B). First, 5.0 mg of GD was dissolved in 2 mL DMSO (10.5 µmol, 5.3 mM)
and the terminal amine deprotonated with 15 molar equivalents of TEA (22.2 µL, 720 g/L). One
molar equivalent of p-SCN-Bn-DFO was then added (10.5 µmol, 33 mM in DMSO). The
reaction was mixed overnight and purified by preparative C18 reverse phase HPLC with a
gradient of 5:95 ACN/H2O (all solvents +0.1% TFA) to 95:5 ACN/H2O over 30 min and a 6
mL/min flow rate (r.t. = 22.9 min). Product was lyophilized and appeared as 5.41 mg (31.5%
yield) of a white powder.

Synthesis was verified by LCMS (ESI+); calculated for

C75H110N16O21S2, 1634.7473; found m/z, 1635.7529 (M+H)+ (Figure 8.5).

Figure 8.5: High resolution mass spectrum of DFO-GD.
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8.2.2 Atomic Force Microscopy of DFO-GD
Samples for AFM were prepared as 2 mM solutions in filtered water (pH adjusted to 7.4
using 0.1 M NaOH) and sonicated for 5 min. Aliquots of 20 µL were then placed onto a freshly
cleaved mica surface (Ted Pella, Inc.) and dried in a dust-free environment prior to imaging.
Images were then generated on a Bruker Multimode 8 AFM using the ScanAsyst in air mode
(Figure 8.6). Micelles formed by GD alone appear slightly oblong, with a diameter between 3060 nm. DFO-GD micelles appear slightly more compact, with diameters ranging in the image
below between 30-40 nm. Importantly, DFO-GD is able to form micelles without the need for
adding unmodified GD.

Figure 8.6: AFM of GD (2 mM) and DFO-GD (2 mM) plated on a mica substrate.
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8.2.3 Dynamic Light Scattering of DFO-GD
Samples were prepared and run for DLS in the same manner as DFO-FFD (Figure 8.7).
The peak corresponding to particles with a hydrodynamic radius of ~80 nm likely indicates
individual micelles in solution, while the larger peak at ~400 nm may indicate aggregated
micelles. Samples of DFO-GD had a high polydispersity index, suggesting there is a large
degree of variability in the particle size in solution.

Figure 8.7: DLS of DFO-GD (2 mM in PBS).

8.2.4 MMP-9 Responsiveness Assay of DFO-GD
It was unknown whether or not the addition of DFO would affect the sequence cleavage
by MMP-9. In order test this in vitro, samples of GD and DFO-GD were mixed with MMP-9
and their relative rates of cleavage evaluated by HPLC. Samples of peptide were prepared at 2
mM in PBS with 1 mM CaCl2 and 5 µM ZnCl2 (pH 7.4), vortexed and sonicated. Next, 5 ng/mL
of MMP-9 (human catalytic domain, recombinant E. coli, Enzo) was added and the mixture
incubated at 37 °C. At prescribed time points, 100 µL aliquots were removed and diluted in 100
µL of a 1:1 mixture of ACN/H2O and run on an analytical C18 reversed phase HPLC on a
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gradient of 0:100 ACN/H2O (+0.1% TFA for all solvents) to 100:0 ACN/H2O over 45 minutes
(Figure 8.8). After 96 hours, most of the starting GD sample (r.t. = 17.1 min) had been cleaved
(r.t. = 13.0 and 13.6 min). DFO-GD on the other hand showed no change in starting peak height
(r.t. = 21.6 min) and only a small possible side-product was visible by 96 h (r.t. = 17.6 min).
Ultimately, this experiment demonstrated that modification of the peptide sequence GD with the
DFO chelator inhibits its cleavage by MMP-9 over the time period studied. For this reason, a
second sequence, GLK was developed to enhance substrate affinity of the negatively charged
enzyme MMP-9.

Figure 8.8: HPLC chromatogram (214 nm) of MMP-9 cleavage of GD-DFO and GD. Blue was
taken immediately after solution was mixed while orange was sampled after 96 hours of
incubation.
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8.2.5 PET Imaging of MMP-9- Negative Tumor-Bearing Mice with [89Zr]Zr-DFO-GD
Despite its lack of enzyme-responsiveness, DFO-GD demonstrated the most
homogeneous and monodisperse micelles of all sequences studied. As such, we decided to test
them as EPR-based imaging agents, capitalizing on the leaky vasculature present in many tumors
to localize the radioactivity.

To this end, athymic nude mice (n=3) were subcutaneously

xenografted with SW1222 colorectal cancer cells and allowed to develop tumors over 4 weeks.
Solutions of 1 mM DFO-GD were then radiolabeled with 89Zr (RCY > 99%). Doses were drawn
of ~200 µCi each in PBS, injected intravenously, and images obtained after 3 and 18 hours.
Maximum intensity projections in Figure 8.9 show very similar clearance to that found in DFOFFD micelles. Clearance through the gut is almost immediate, with some retained within the
gallbladder and kidneys. Almost no activity remains within the blood pool, likely contributing to
the total absence of uptake within the sizable left-shoulder tumors (~200-300 cm3). The rapid
biliary excretion seen in the anionic GD sequence suggests OATP or similar pathways are again
playing a role in clearing these micelles. Given the unsuccessful imaging of two radiolabeled
micellar nanoparticles based on negatively charged subunits, we decided that /in vivo testing of
the positively charged GLK may prove more effective.
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Figure 8.9: PET imaging of athymic nude mice bearing subcutaneous left-shoulder SW1222
xenografts injected with [89Zr]Zr-DFO-GD (1 mM). Images displayed are maximum intensity
projections. No visible tumor uptake was observed.

8.2.6 Synthesis of DFO-GLK
The peptide sequence GLK was modified on its N-terminus with p-SCN-BnDeferoxamine (DFO) (Figure 7.3C). The sequence was purchased bearing boc protecting groups
on its two lysine residues: FFGALGLK(boc)GK(boc).

First, 10.0 mg of GLK(boc)2 was

dissolved in 500 µL DMSO (12.1 µmol) and the terminal amine deprotonated with 15 molar
equivalents of TEA (25.5 µL, 720 g/L). One molar equivalent of p-SCN-Bn-DFO was then
added (12.1 µmol, 27 mM in DMSO). The reaction was mixed overnight and purified by
preparative C18 reverse phase HPLC with a gradient of 5:95 ACN/H2O (all solvents +0.1% TFA)
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to 95:5 ACN/H2O over 30 min and a 6 mL/min flow rate (r.t. = 27.6 min). Product was
lyophilized and the resulting DFO-GLK(boc)2 was set for deprotection under relatively mild
conditions: 1% TFA in 1:1 H2O:ACN overnight. Addition of more TFA resulted in rapid
product degradation. Deprotected DFO-GLK was purified by HPLC with a gradient of 5:95
ACN/H2O (all solvents +0.1% TFA) to 95:5 ACN/H2O over 30 min and a 6 mL/min flow rate
(r.t. = 20.8 min). Product was lyophilized and resulted in 0.5 mg of white powder (2.3% yield).
Synthesis was verified by LCMS (ESI+); calculated for C84H132N20O19S2, 1788.94; found m/z,
1810.1 (M+Na)+ (Figure 8.10: Mass spectrometry of DFO-GLK).

Figure 8.10: Mass spectrometry of DFO-GLK

8.2.7 Dynamic Light Scattering of DFO-GLK
Samples were prepared and run for DLS in the same manner as DFO-FFD (Figure 8.11).
One small peak ~170 nm was observed, likely indicating individual micelles in solution, while
the larger peak at ~700 nm may indicate aggregated micelles.
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These micelles had a high

polydispersity index (>0.7) and poor multimodal fit, suggesting there is a high degree of sizevariability in particles present in solution.

Figure 8.11: DLS of DFO-GLK (2 mM)

8.2.8 Imaging of DFO-GLK
Finally, once synthesis and characterization of DFO-GLK was completed, micelles were
radiolabeled with

89

Zr as described previously and injected into athymic nude mice (n = 5)

bearing subcutaneous SW1222 xenografts. This experiment sought to test micelles stability and
pharmacokinetics in vivo and so an MMP-9-negative cell line was chosen. Each mouse was
administered 240 µCi of a 1 mM solution of [89Zr]Zr-DFO-GLK by tail vein injection and
imaged 1 and 18 hours afterwards (Figure 8.12). Even one hour post-injection there is a stark
contrast between mice administered DFO-GLK and those administered either DFO-GD or DFOFFD. While some activity can be seen in the intestines, significantly more is present in the liver
and spleen, suggesting the micelles are able to accumulate there without being broken down and
cleared. Additionally, activity can be clearly seen in the blood at 1 h, while none was detectable
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in either DFO-GD or DFO-FFD. Perhaps most excitingly, in mouse 1 it can be clearly seen that
there is activity present, though it has mostly cleared by 18 h. It is unclear if this is uptake due to
the enhanced permeability and retention of the leaky tumor vasculature, however there is
certainly a longer blood circulation time with the GLK micelles than the other peptides tested.
While speculative, it is quite likely that the positive charge imparted by the lysine residues in
GLK contributes to this shift in pharmacokinetics. Such information will likely prove invaluable
to the development of future peptide micelle-based radiotracers.

Figure 8.12: PET images of [89Zr]Zr-DFO-GLK micelles 1 and 18 hours after tail vein injection
into athymic nude mice bearing SW1222 xenografts. White arrow indicates tumor uptake in
Mouse 1.

8.3 Conclusion
The development of nanomaterials for applications in biomedicine is an exciting and
developing area of research that holds a great deal of promise. Their relatively large size and
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complex surface properties allow nanoparticles to interact in unique ways with living cells, and
their ability to be manipulated and fine-tuned presents a near-infinity of possibilities. The
complexity of these systems requires a great deal of effort and interdisciplinary collaboration to
better understand how nanostructures behave in living organisms. In the preceding pages we
discuss how SAPA micelles can be modified to bear the radiometal chelator DFO and how it
affects the micelle behavior in vitro. While this structural change does not always alter the
supramolecular self-assembly, it significantly impairs MMP-9 cleavage. It is possible that the
large size of the DFO somehow obstructs enzyme binding or substrate recognition. PET imaging
of the radiolabeled micelles also illustrated a systemic problem. Clearance of the injected
micelles for the two aspartic acid-containing sequences happened almost immediately, with no
observable activity remaining in the blood after only 3 hours. This demonstrates rapid clearance,
possibly through OATP-mediated pathways, as discussed above.

An administered SAPA

requires sufficient time in order to be recognized and cleaved by MMP-9, therefore if future
applications of this technology are to be effective, overall circulation time must be significantly
extended, possibly through the alteration of surface charge. This can be seen in the PET images
of [89Zr]Zr-DFO-GLK micelles where blood circulation time was increased, leading to
observable activity within the tumor. There is a great deal to learn about how nanoparticles
interact with the body and, as the field grows, it is important to explore it rigorously and
systematically.
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